Trial Outcomes & Findings for Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001) (NCT NCT03396445)

Last Updated: 2025-11-05

Results Overview

DLTs were assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events version 5. A DLT was defined as any of the following events: Grade 4 nonhematologic toxicity; Grade 4 hematologic toxicity lasting ≥7 days, except thrombocytopenia; Grade 4 thrombocytopenia; Grade 3 thrombocytopenia requiring a platelet transfusion; Nonhematologic adverse event (AE) Grade ≥3, with exceptions; Grade 3 or 4 nonhematologic laboratory abnormality; Prolonged delay (\>2 weeks) in initiating Cycle 2 due to treatment-related toxicity; Treatment-related toxicity resulting in study drug discontinuation during the DLT evaluation period; Missing \>25% of any study drug during the DLT evaluation period due to a treatment-related AE; or Grade 5 toxicity. The number of participants who experienced one or more DLTs is reported.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

182 participants

Primary outcome timeframe

Up to 21 days in Cycle 1

Results posted on

2025-11-05

Participant Flow

Per protocol, pharmacokinetic (PK) outcome measures were not analyzed separately for the switch-over treatment arms.

Participant milestones

Participant milestones
Measure	Arm 1 Boserolimab 2 mg Q3W Participants received boserolimab 2 mg via intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long	Arm 1 Boserolimab 7 mg Q3W Participants received boserolimab 7 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 20 mg Q3W Participants received boserolimab 20 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 70 mg Q3W Participants received boserolimab 70 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 200 mg Q3W Participants received boserolimab 200 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 700 mg Q3W Participants received boserolimab 700 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1a Boserolimab 30 mg Q3W (Endometrial) Participants with endometrial cancer received boserolimab 30 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 2 mg Q3W + Pembrolizumab 200 mg Q3W Participants received separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 7 mg Q3W + Pembrolizumab 200 mg Q3W Participants received separate IV infusions of boserolimab 7 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 20 mg Q3W + Pembrolizumab 200 mg Q3W Participants received separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 70 mg Q3W + Pembrolizumab 200 mg Q3W Participants received separate IV infusions of boserolimab 70 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 200 mg Q3W + Pembrolizumab 200 mg Q3W Participants received separate IV infusions of boserolimab 200 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2a Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W (TNBC) Participants with triple-negative breast cancer (TNBC) received separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2b Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W (Endometrial) Participants with endometrial cancer received separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2c Boserolimab 30 mg Q6W + Pembrolizumab 400 mg Q6W (Endometrial) Participants with endometrial cancer received separate IV infusions of boserolimab 30 mg and pembrolizumab 400 mg. Boserolimab was administered once Q6W on Day 1 of each cycle for a total of up to approximately 4 cycles (up to approximately 6 months). Pembrolizumab was administered once every 6 weeks (Q6W) on Day 1 of each cycle for a total of up to approximately 18 cycles (up to approximately 27 months). Each cycle was 6 weeks long.	Arm 3 Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W + Pemetrexed + Carboplatin (NSCLC) Participants with non-small cell lung cancer (NSCLC) received separate IV infusions of boserolimab 30 mg, pembrolizumab 200 mg, pemetrexed 500 mg/m\^2, and carboplatin area under the curve (AUC) 5 mg/mL/min. Boserolimab was administered once Q3W on Day 1 of each cycle for a total of up to approximately 8 cycles (up to approximately 6 months). Pembrolizumab and pemetrexed were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Carboplatin was administered once Q3W on Day 1 of each cycle for a total of up to approximately 4 cycles (up to approximately 3 months). Each cycle was 3 weeks long.	Arm 4 Boserolimab 30 mg Q6W + Pembrolizumab 400 mg Q6W + Nab-paclitaxel (TNBC) Participants with TNBC received separate IV infusions of boserolimab 30 mg, pembrolizumab 400 mg, and nab-paclitaxel 100 mg/m\^2. Boserolimab and pembrolizumab were administered once Q6W on Day 1 of each cycle for a total of up to approximately 18 cycles (up to approximately 27 months). Nab-paclitaxel was administered on a 3-weeks on/1-week off schedule every 28 days (Days 1, 8, 15, 29, and 36 of odd-numbered cycles and Days 1, 15, 22, and 29 of even-numbered cycles). Each cycle was 6 weeks long.	Switch-over Arm 1 Boserolimab 2 mg Q3W To Boserolimab 2 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 2 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 7 mg Q3W To Boserolimab 2 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 7 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 20 mg Q3W To Boserolimab 7 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 20 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 7 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 20 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 20 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 70 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 70 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 70 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 70 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 200 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 200 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1a Boserolimab 30mg Q3W (Endometrial) To Boserolimab 30mg + Pembrolizumab 200mg Q3W Qualified participants who received boserolimab 30 mg via IV infusion in Arm 1a but experienced disease progression switched over to receive separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.
Treatment Period Treated	3	3	6	3	8	2	14	3	3	3	7	14	30	15	13	10	41	0	0	0	0	0	0	0	0	0
Treatment Period NOT COMPLETED	3	3	6	3	9	2	14	3	3	4	7	12	30	14	13	8	19	0	0	0	0	0	0	0	0	0
Switch-over Period STARTED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	2	3	2	2	2	1	9
Switch-over Period Treated	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	2	3	2	2	2	1	9
Switch-over Period NOT COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	2	1	2	1	1	6
Treatment Period STARTED	3	3	6	3	9	2	14	3	3	4	7	14	31	15	14	10	41	0	0	0	0	0	0	0	0	0
Treatment Period COMPLETED	0	0	0	0	0	0	0	0	0	0	0	2	1	1	1	2	22	0	0	0	0	0	0	0	0	0
Switch-over Period COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	1	0	1	0	3

Reasons for withdrawal

Reasons for withdrawal
Measure	Arm 1 Boserolimab 2 mg Q3W Participants received boserolimab 2 mg via intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long	Arm 1 Boserolimab 7 mg Q3W Participants received boserolimab 7 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 20 mg Q3W Participants received boserolimab 20 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 70 mg Q3W Participants received boserolimab 70 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 200 mg Q3W Participants received boserolimab 200 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 700 mg Q3W Participants received boserolimab 700 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1a Boserolimab 30 mg Q3W (Endometrial) Participants with endometrial cancer received boserolimab 30 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 2 mg Q3W + Pembrolizumab 200 mg Q3W Participants received separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 7 mg Q3W + Pembrolizumab 200 mg Q3W Participants received separate IV infusions of boserolimab 7 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 20 mg Q3W + Pembrolizumab 200 mg Q3W Participants received separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 70 mg Q3W + Pembrolizumab 200 mg Q3W Participants received separate IV infusions of boserolimab 70 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 200 mg Q3W + Pembrolizumab 200 mg Q3W Participants received separate IV infusions of boserolimab 200 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2a Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W (TNBC) Participants with triple-negative breast cancer (TNBC) received separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2b Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W (Endometrial) Participants with endometrial cancer received separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2c Boserolimab 30 mg Q6W + Pembrolizumab 400 mg Q6W (Endometrial) Participants with endometrial cancer received separate IV infusions of boserolimab 30 mg and pembrolizumab 400 mg. Boserolimab was administered once Q6W on Day 1 of each cycle for a total of up to approximately 4 cycles (up to approximately 6 months). Pembrolizumab was administered once every 6 weeks (Q6W) on Day 1 of each cycle for a total of up to approximately 18 cycles (up to approximately 27 months). Each cycle was 6 weeks long.	Arm 3 Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W + Pemetrexed + Carboplatin (NSCLC) Participants with non-small cell lung cancer (NSCLC) received separate IV infusions of boserolimab 30 mg, pembrolizumab 200 mg, pemetrexed 500 mg/m\^2, and carboplatin area under the curve (AUC) 5 mg/mL/min. Boserolimab was administered once Q3W on Day 1 of each cycle for a total of up to approximately 8 cycles (up to approximately 6 months). Pembrolizumab and pemetrexed were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Carboplatin was administered once Q3W on Day 1 of each cycle for a total of up to approximately 4 cycles (up to approximately 3 months). Each cycle was 3 weeks long.	Arm 4 Boserolimab 30 mg Q6W + Pembrolizumab 400 mg Q6W + Nab-paclitaxel (TNBC) Participants with TNBC received separate IV infusions of boserolimab 30 mg, pembrolizumab 400 mg, and nab-paclitaxel 100 mg/m\^2. Boserolimab and pembrolizumab were administered once Q6W on Day 1 of each cycle for a total of up to approximately 18 cycles (up to approximately 27 months). Nab-paclitaxel was administered on a 3-weeks on/1-week off schedule every 28 days (Days 1, 8, 15, 29, and 36 of odd-numbered cycles and Days 1, 15, 22, and 29 of even-numbered cycles). Each cycle was 6 weeks long.	Switch-over Arm 1 Boserolimab 7 mg Q3W To Boserolimab 2 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 7 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 20 mg Q3W To Boserolimab 7 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 20 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 7 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 20 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 20 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 70 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 70 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 70 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 70 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 200 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 200 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1a Boserolimab 30mg Q3W (Endometrial) To Boserolimab 30mg + Pembrolizumab 200mg Q3W Qualified participants who received boserolimab 30 mg via IV infusion in Arm 1a but experienced disease progression switched over to receive separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.
Treatment Period Death	2	2	1	1	3	2	5	3	3	3	7	12	28	14	10	8	18	0	0	0	0	0	0	0	0
Treatment Period Lost to Follow-up	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0
Treatment Period Physician Decision	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Treatment Period Randomized by Mistake without Study Treatment	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0
Treatment Period Progressive Disease, Switched Over to Boserolimab + Pembrolizumab Combination Treatment	1	1	5	2	5	0	9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Switch-over Period Death	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	2	1	2	0	1	6
Switch-over Period Lost to Follow-up	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Treatment Period Withdrawal by Subject	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0

Baseline Characteristics

Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Arm 1a Boserolimab 30 mg Q3W (Endometrial) n=14 Participants Participants with endometrial cancer received boserolimab 30 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 700 mg Q3W n=2 Participants Participants received boserolimab 700 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 2 mg Q3W n=3 Participants Participants received boserolimab 2 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 7 mg Q3W n=3 Participants Participants received boserolimab 7 mg via intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long	Arm 1 Boserolimab 20 mg Q3W n=6 Participants Participants received boserolimab 20 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 70 mg Q3W n=3 Participants Participants received boserolimab 70 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 200 mg Q3W n=9 Participants Participants received boserolimab 200 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 2 mg Q3W + Pembrolizumab 200 mg Q3W n=3 Participants Participants received separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 7 mg Q3W + Pembrolizumab 200 mg Q3W n=3 Participants Participants received separate IV infusions of boserolimab 7 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 20 mg Q3W + Pembrolizumab 200 mg Q3W n=4 Participants Participants received separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 70 mg Q3W + Pembrolizumab 200 mg Q3W n=7 Participants Participants received separate IV infusions of boserolimab 70 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 200 mg Q3W + Pembrolizumab 200 mg Q3W n=14 Participants Participants received separate IV infusions of boserolimab 200 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2a Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W (TNBC) n=31 Participants Participants with triple-negative breast cancer (TNBC) received separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2b Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W (Endometrial) n=15 Participants Participants with endometrial cancer received separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2c Boserolimab 30 mg Q6W + Pembrolizumab 400 mg Q6W (Endometrial) n=14 Participants Participants with endometrial cancer received separate IV infusions of boserolimab 30 mg and pembrolizumab 400 mg. Boserolimab was administered once Q6W on Day 1 of each cycle for a total of up to approximately 4 cycles (up to approximately 6 months). Pembrolizumab was administered once Q6W on Day 1 of each cycle for a total of up to approximately 18 cycles (up to approximately 27 months). Each cycle was 6 weeks long.	Arm 3 Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W + Pemetrexed + Carboplatin (NSCLC) n=10 Participants Participants with non-small cell lung cancer (NSCLC) received separate IV infusions of boserolimab 30 mg, pembrolizumab 200 mg, pemetrexed 500 mg/m\^2, and carboplatin area under the curve (AUC) 5 mg/mL/min. Boserolimab was administered once Q3W on Day 1 of each cycle for a total of up to approximately 8 cycles (up to approximately 6 months). Pembrolizumab and pemetrexed were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Carboplatin was administered once Q3W on Day 1 of each cycle for a total of up to approximately 4 cycles (up to approximately 3 months). Each cycle was 3 weeks long.	Arm 4 Boserolimab 30 mg Q6W + Pembrolizumab 400 mg Q6W + Nab-paclitaxel (TNBC) n=41 Participants Participants with TNBC received separate IV infusions of boserolimab 30 mg, pembrolizumab 400 mg, and nab-paclitaxel 100 mg/m\^2. Boserolimab and pembrolizumab were administered once Q6W on Day 1 of each cycle for a total of up to approximately 18 cycles (up to approximately 27 months). Nab-paclitaxel was administered on a 3-weeks on/1-week off schedule every 28 days (Days 1, 8, 15, 29, and 36 of odd-numbered cycles and Days 1, 15, 22, and 29 of even-numbered cycles). Each cycle was 6 weeks long.	Total n=182 Participants Total of all reporting groups
Age, Continuous	71.6 Years STANDARD_DEVIATION 5.7 • n=8 Participants	61.0 Years STANDARD_DEVIATION 2.8 • n=7 Participants	55.3 Years STANDARD_DEVIATION 18.9 • n=15 Participants	57.3 Years STANDARD_DEVIATION 18.0 • n=161 Participants	57.0 Years STANDARD_DEVIATION 15.8 • n=100 Participants	54.0 Years STANDARD_DEVIATION 15.7 • n=3 Participants	61.6 Years STANDARD_DEVIATION 14.2 • n=8 Participants	44.7 Years STANDARD_DEVIATION 15.6 • n=8 Participants	50.0 Years STANDARD_DEVIATION 24.3 • n=8 Participants	61.5 Years STANDARD_DEVIATION 6.2 • n=68 Participants	59.9 Years STANDARD_DEVIATION 7.2 • n=4 Participants	55.1 Years STANDARD_DEVIATION 16.1 • n=44 Participants	50.4 Years STANDARD_DEVIATION 13.3 • n=5 Participants	64.6 Years STANDARD_DEVIATION 7.1 • n=20 Participants	68.5 Years STANDARD_DEVIATION 9.5 • n=6 Participants	61.9 Years STANDARD_DEVIATION 9.4 • n=1 Participants	51.7 Years STANDARD_DEVIATION 11.8 • n=7 Participants	57.5 Years STANDARD_DEVIATION 13.6 • n=6 Participants
Sex: Female, Male Female	14 Participants n=8 Participants	2 Participants n=7 Participants	2 Participants n=15 Participants	1 Participants n=161 Participants	2 Participants n=100 Participants	2 Participants n=3 Participants	5 Participants n=8 Participants	2 Participants n=8 Participants	0 Participants n=8 Participants	1 Participants n=68 Participants	7 Participants n=4 Participants	10 Participants n=44 Participants	31 Participants n=5 Participants	15 Participants n=20 Participants	14 Participants n=6 Participants	6 Participants n=1 Participants	41 Participants n=7 Participants	155 Participants n=6 Participants
Sex: Female, Male Male	0 Participants n=8 Participants	0 Participants n=7 Participants	1 Participants n=15 Participants	2 Participants n=161 Participants	4 Participants n=100 Participants	1 Participants n=3 Participants	4 Participants n=8 Participants	1 Participants n=8 Participants	3 Participants n=8 Participants	3 Participants n=68 Participants	0 Participants n=4 Participants	4 Participants n=44 Participants	0 Participants n=5 Participants	0 Participants n=20 Participants	0 Participants n=6 Participants	4 Participants n=1 Participants	0 Participants n=7 Participants	27 Participants n=6 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=8 Participants	0 Participants n=7 Participants	0 Participants n=15 Participants	0 Participants n=161 Participants	0 Participants n=100 Participants	0 Participants n=3 Participants	1 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=68 Participants	1 Participants n=4 Participants	0 Participants n=44 Participants	0 Participants n=5 Participants	0 Participants n=20 Participants	1 Participants n=6 Participants	0 Participants n=1 Participants	11 Participants n=7 Participants	14 Participants n=6 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	14 Participants n=8 Participants	2 Participants n=7 Participants	3 Participants n=15 Participants	3 Participants n=161 Participants	6 Participants n=100 Participants	3 Participants n=3 Participants	5 Participants n=8 Participants	3 Participants n=8 Participants	3 Participants n=8 Participants	4 Participants n=68 Participants	6 Participants n=4 Participants	14 Participants n=44 Participants	26 Participants n=5 Participants	14 Participants n=20 Participants	13 Participants n=6 Participants	9 Participants n=1 Participants	30 Participants n=7 Participants	158 Participants n=6 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=8 Participants	0 Participants n=7 Participants	0 Participants n=15 Participants	0 Participants n=161 Participants	0 Participants n=100 Participants	0 Participants n=3 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	00 Participants n=8 Participants	0 Participants n=68 Participants	0 Participants n=4 Participants	0 Participants n=44 Participants	0 Participants n=5 Participants	0 Participants n=20 Participants	0 Participants n=6 Participants	0 Participants n=1 Participants	0 Participants n=7 Participants	0 Participants n=6 Participants
Race (NIH/OMB) Asian	0 Participants n=8 Participants	0 Participants n=7 Participants	0 Participants n=15 Participants	0 Participants n=161 Participants	0 Participants n=100 Participants	0 Participants n=3 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=68 Participants	0 Participants n=4 Participants	1 Participants n=44 Participants	0 Participants n=5 Participants	0 Participants n=20 Participants	0 Participants n=6 Participants	0 Participants n=1 Participants	15 Participants n=7 Participants	16 Participants n=6 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=8 Participants	0 Participants n=7 Participants	0 Participants n=15 Participants	0 Participants n=161 Participants	0 Participants n=100 Participants	0 Participants n=3 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=68 Participants	0 Participants n=4 Participants	0 Participants n=44 Participants	0 Participants n=5 Participants	0 Participants n=20 Participants	0 Participants n=6 Participants	0 Participants n=1 Participants	0 Participants n=7 Participants	0 Participants n=6 Participants
Race (NIH/OMB) Black or African American	1 Participants n=8 Participants	0 Participants n=7 Participants	0 Participants n=15 Participants	0 Participants n=161 Participants	0 Participants n=100 Participants	0 Participants n=3 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=68 Participants	0 Participants n=4 Participants	0 Participants n=44 Participants	0 Participants n=5 Participants	2 Participants n=20 Participants	0 Participants n=6 Participants	0 Participants n=1 Participants	0 Participants n=7 Participants	3 Participants n=6 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=8 Participants	0 Participants n=7 Participants	0 Participants n=15 Participants	0 Participants n=161 Participants	0 Participants n=100 Participants	0 Participants n=3 Participants	3 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=68 Participants	0 Participants n=4 Participants	0 Participants n=44 Participants	1 Participants n=5 Participants	0 Participants n=20 Participants	0 Participants n=6 Participants	0 Participants n=1 Participants	0 Participants n=7 Participants	4 Participants n=6 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=8 Participants	0 Participants n=7 Participants	0 Participants n=15 Participants	0 Participants n=161 Participants	0 Participants n=100 Participants	0 Participants n=3 Participants	3 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=68 Participants	0 Participants n=4 Participants	0 Participants n=44 Participants	5 Participants n=5 Participants	1 Participants n=20 Participants	0 Participants n=6 Participants	1 Participants n=1 Participants	0 Participants n=7 Participants	10 Participants n=6 Participants
Race (NIH/OMB) White	13 Participants n=8 Participants	2 Participants n=7 Participants	3 Participants n=15 Participants	3 Participants n=161 Participants	6 Participants n=100 Participants	3 Participants n=3 Participants	6 Participants n=8 Participants	3 Participants n=8 Participants	3 Participants n=8 Participants	4 Participants n=68 Participants	7 Participants n=4 Participants	13 Participants n=44 Participants	30 Participants n=5 Participants	13 Participants n=20 Participants	14 Participants n=6 Participants	10 Participants n=1 Participants	26 Participants n=7 Participants	159 Participants n=6 Participants
Race (NIH/OMB) More than one race	0 Participants n=8 Participants	0 Participants n=7 Participants	0 Participants n=15 Participants	0 Participants n=161 Participants	0 Participants n=100 Participants	0 Participants n=3 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=68 Participants	0 Participants n=4 Participants	0 Participants n=44 Participants	0 Participants n=5 Participants	0 Participants n=20 Participants	0 Participants n=6 Participants	0 Participants n=1 Participants	0 Participants n=7 Participants	0 Participants n=6 Participants

PRIMARY outcome

Timeframe: Up to 21 days in Cycle 1

Population: All participants in Arms 1, 1a, 2, 2a, 2b, 2c, and Switch-over Arms who received ≥1 dose of study treatment and who were observed for DLTs for up to 21 days following the first dose of study treatment in Cycle 1. As pre-specified in the protocol, DLTs were analyzed separately for the Switch-over Arms.

Outcome measures

Outcome measures
Measure	Arm 1 Boserolimab 2 mg Q3W n=3 Participants Participants received boserolimab 2 mg via intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long	Arm 1 Boserolimab 7 mg Q3W n=3 Participants Participants received boserolimab 7 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 20 mg Q3W n=6 Participants Participants received boserolimab 20 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 70 mg Q3W n=3 Participants Participants received boserolimab 70 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 200 mg Q3W n=8 Participants Participants received boserolimab 200 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 700 mg Q3W n=2 Participants Participants received boserolimab 700 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1a Boserolimab 30 mg Q3W (Endometrial) n=14 Participants Participants with endometrial cancer received boserolimab 30 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 20 mg Q3W + Pembrolizumab 200 mg Q3W n=3 Participants Participants received separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 70 mg Q3W + Pembrolizumab 200 mg Q3W n=7 Participants Participants received separate IV infusions of boserolimab 70 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 200 mg Q3W + Pembrolizumab 200 mg Q3W n=14 Participants Participants received separate IV infusions of boserolimab 200 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2a Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W (TNBC) n=30 Participants Participants with triple-negative breast cancer (TNBC) received separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2b Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W (Endometrial) n=15 Participants Participants with endometrial cancer received separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2c Boserolimab 30 mg Q6W + Pembrolizumab 400 mg Q6W (Endometrial) n=13 Participants Participants with endometrial cancer received separate IV infusions of boserolimab 30 mg and pembrolizumab 400 mg. Boserolimab was administered once Q6W on Day 1 of each cycle for a total of up to approximately 4 cycles (up to approximately 6 months). Pembrolizumab was administered once Q6W on Day 1 of each cycle for a total of up to approximately 18 cycles (up to approximately 27 months). Each cycle was 6 weeks long.	Arm 2 Boserolimab 2 mg Q3W + Pembrolizumab 200 mg Q3W n=3 Participants Participants received separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 7 mg Q3W + Pembrolizumab 200 mg Q3W n=3 Participants Participants received separate IV infusions of boserolimab 7 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 2 mg Q3W To Boserolimab 2 mg + Pembrolizumab 200 mg Q3W n=1 Participants Qualified participants who received boserolimab 2 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 7 mg Q3W To Boserolimab 2 mg + Pembrolizumab 200 mg Q3W n=1 Participants Qualified participants who received boserolimab 7 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 20 mg Q3W To Boserolimab 7 mg + Pembrolizumab 200 mg Q3W n=2 Participants Qualified participants who received boserolimab 20 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 7 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 20 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W n=3 Participants Qualified participants who received boserolimab 20 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 70 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W n=2 Participants Qualified participants who received boserolimab 70 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W n=2 Participants Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 70 mg + Pembrolizumab 200 mg Q3W n=2 Participants Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 70 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 200 mg + Pembrolizumab 200 mg Q3W n=1 Participants Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 200 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1a Boserolimab 30mg Q3W (Endometrial) To Boserolimab 30mg + Pembrolizumab 200mg Q3W n=9 Participants Qualified participants who received boserolimab 30 mg via IV infusion in Arm 1a but experienced disease progression switched over to receive separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.
Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT)	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	2 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants

PRIMARY outcome

Timeframe: Up to approximately 78 months

Population: All participants in Arms 1, 1a, 2, 2a, 2b, 2c, and Switch-over Arms who received ≥1 dose of study treatment. As pre-specified in the protocol, safety data were analyzed separately for the Switch-over Arms.

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experienced one or more AEs is reported.

Outcome measures

Outcome measures
Measure	Arm 1 Boserolimab 2 mg Q3W n=3 Participants Participants received boserolimab 2 mg via intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long	Arm 1 Boserolimab 7 mg Q3W n=3 Participants Participants received boserolimab 7 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 20 mg Q3W n=6 Participants Participants received boserolimab 20 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 70 mg Q3W n=3 Participants Participants received boserolimab 70 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 200 mg Q3W n=8 Participants Participants received boserolimab 200 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 700 mg Q3W n=2 Participants Participants received boserolimab 700 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1a Boserolimab 30 mg Q3W (Endometrial) n=14 Participants Participants with endometrial cancer received boserolimab 30 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 20 mg Q3W + Pembrolizumab 200 mg Q3W n=3 Participants Participants received separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 70 mg Q3W + Pembrolizumab 200 mg Q3W n=7 Participants Participants received separate IV infusions of boserolimab 70 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 200 mg Q3W + Pembrolizumab 200 mg Q3W n=14 Participants Participants received separate IV infusions of boserolimab 200 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2a Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W (TNBC) n=30 Participants Participants with triple-negative breast cancer (TNBC) received separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2b Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W (Endometrial) n=15 Participants Participants with endometrial cancer received separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2c Boserolimab 30 mg Q6W + Pembrolizumab 400 mg Q6W (Endometrial) n=13 Participants Participants with endometrial cancer received separate IV infusions of boserolimab 30 mg and pembrolizumab 400 mg. Boserolimab was administered once Q6W on Day 1 of each cycle for a total of up to approximately 4 cycles (up to approximately 6 months). Pembrolizumab was administered once Q6W on Day 1 of each cycle for a total of up to approximately 18 cycles (up to approximately 27 months). Each cycle was 6 weeks long.	Arm 2 Boserolimab 2 mg Q3W + Pembrolizumab 200 mg Q3W n=3 Participants Participants received separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 7 mg Q3W + Pembrolizumab 200 mg Q3W n=3 Participants Participants received separate IV infusions of boserolimab 7 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 2 mg Q3W To Boserolimab 2 mg + Pembrolizumab 200 mg Q3W n=1 Participants Qualified participants who received boserolimab 2 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 7 mg Q3W To Boserolimab 2 mg + Pembrolizumab 200 mg Q3W n=1 Participants Qualified participants who received boserolimab 7 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 20 mg Q3W To Boserolimab 7 mg + Pembrolizumab 200 mg Q3W n=2 Participants Qualified participants who received boserolimab 20 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 7 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 20 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W n=3 Participants Qualified participants who received boserolimab 20 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 70 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W n=2 Participants Qualified participants who received boserolimab 70 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W n=2 Participants Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 70 mg + Pembrolizumab 200 mg Q3W n=2 Participants Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 70 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 200 mg + Pembrolizumab 200 mg Q3W n=1 Participants Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 200 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1a Boserolimab 30mg Q3W (Endometrial) To Boserolimab 30mg + Pembrolizumab 200mg Q3W n=9 Participants Qualified participants who received boserolimab 30 mg via IV infusion in Arm 1a but experienced disease progression switched over to receive separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.
Number of Participants With One or More AEs	3 Participants	3 Participants	6 Participants	3 Participants	8 Participants	2 Participants	14 Participants	3 Participants	7 Participants	14 Participants	30 Participants	15 Participants	13 Participants	3 Participants	3 Participants	1 Participants	1 Participants	2 Participants	3 Participants	2 Participants	2 Participants	2 Participants	1 Participants	8 Participants

PRIMARY outcome

Timeframe: Up to 23 months

Outcome measures

Outcome measures
Measure	Arm 1 Boserolimab 2 mg Q3W n=3 Participants Participants received boserolimab 2 mg via intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long	Arm 1 Boserolimab 7 mg Q3W n=3 Participants Participants received boserolimab 7 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 20 mg Q3W n=6 Participants Participants received boserolimab 20 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 70 mg Q3W n=3 Participants Participants received boserolimab 70 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 200 mg Q3W n=8 Participants Participants received boserolimab 200 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 700 mg Q3W n=2 Participants Participants received boserolimab 700 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1a Boserolimab 30 mg Q3W (Endometrial) n=14 Participants Participants with endometrial cancer received boserolimab 30 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 20 mg Q3W + Pembrolizumab 200 mg Q3W n=3 Participants Participants received separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 70 mg Q3W + Pembrolizumab 200 mg Q3W n=7 Participants Participants received separate IV infusions of boserolimab 70 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 200 mg Q3W + Pembrolizumab 200 mg Q3W n=14 Participants Participants received separate IV infusions of boserolimab 200 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2a Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W (TNBC) n=30 Participants Participants with triple-negative breast cancer (TNBC) received separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2b Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W (Endometrial) n=15 Participants Participants with endometrial cancer received separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2c Boserolimab 30 mg Q6W + Pembrolizumab 400 mg Q6W (Endometrial) n=13 Participants Participants with endometrial cancer received separate IV infusions of boserolimab 30 mg and pembrolizumab 400 mg. Boserolimab was administered once Q6W on Day 1 of each cycle for a total of up to approximately 4 cycles (up to approximately 6 months). Pembrolizumab was administered once Q6W on Day 1 of each cycle for a total of up to approximately 18 cycles (up to approximately 27 months). Each cycle was 6 weeks long.	Arm 2 Boserolimab 2 mg Q3W + Pembrolizumab 200 mg Q3W n=3 Participants Participants received separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 7 mg Q3W + Pembrolizumab 200 mg Q3W n=3 Participants Participants received separate IV infusions of boserolimab 7 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 2 mg Q3W To Boserolimab 2 mg + Pembrolizumab 200 mg Q3W n=1 Participants Qualified participants who received boserolimab 2 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 7 mg Q3W To Boserolimab 2 mg + Pembrolizumab 200 mg Q3W n=1 Participants Qualified participants who received boserolimab 7 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 20 mg Q3W To Boserolimab 7 mg + Pembrolizumab 200 mg Q3W n=2 Participants Qualified participants who received boserolimab 20 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 7 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 20 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W n=3 Participants Qualified participants who received boserolimab 20 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 70 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W n=2 Participants Qualified participants who received boserolimab 70 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W n=2 Participants Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 70 mg + Pembrolizumab 200 mg Q3W n=2 Participants Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 70 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 200 mg + Pembrolizumab 200 mg Q3W n=1 Participants Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 200 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1a Boserolimab 30mg Q3W (Endometrial) To Boserolimab 30mg + Pembrolizumab 200mg Q3W n=9 Participants Qualified participants who received boserolimab 30 mg via IV infusion in Arm 1a but experienced disease progression switched over to receive separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.
Number of Participants Who Discontinued Study Treatment Due to an AE	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	2 Participants	0 Participants	0 Participants	1 Participants	1 Participants	4 Participants	1 Participants	2 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	2 Participants

SECONDARY outcome

Timeframe: Predose Day 1 Cycle 1 and at designated timepoints up to Day 1 Cycle 2

Population: All participants who complied with the protocol sufficiently to ensure that the data was likely to exhibit the effects of treatment, according to the underlying scientific model, and who had available AUC0-last data from ≥1 study treatment. As pre-specified in the protocol, PK outcomes were not analyzed separately for the Switch-over Arms.

AUC0-last was defined as the area under the concentration versus time curve for boserolimab from 0 to the time of the last quantifiable concentration in serum. Samples were taken predose and at specified times postdose to determine the AUC0-last of boserolimab. PK collection time frames include: Arms 1, 2 (Cycle = 3 weeks): Predose, at start \& end of infusion on Day 1 Cycle 1, Days 2, 3, 5, 8, 15 of Cycle 1, and predose on Day 1 of Cycle 2; Arms 1a, 2a, 2b, 3 (Cycle = 3 weeks): Predose, at start \& end of infusion on Day 1 Cycle 1, Days 2, 3, 8, 15 of Cycle 1, and predose on Day 1 of Cycle 2; Arms 2c and 4 (Cycle = 6 weeks): Predose, at start \& end of infusion on Day 1 Cycle 1, Days 2, 3, 8, 15, 22 of Cycle 1, and predose on Day 1 of Cycle 2.

Outcome measures

Outcome measures
Measure	Arm 1 Boserolimab 2 mg Q3W n=3 Participants Participants received boserolimab 2 mg via intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long	Arm 1 Boserolimab 7 mg Q3W n=1 Participants Participants received boserolimab 7 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 20 mg Q3W n=3 Participants Participants received boserolimab 20 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 70 mg Q3W n=3 Participants Participants received boserolimab 70 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 200 mg Q3W n=8 Participants Participants received boserolimab 200 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 700 mg Q3W n=2 Participants Participants received boserolimab 700 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1a Boserolimab 30 mg Q3W (Endometrial) n=14 Participants Participants with endometrial cancer received boserolimab 30 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 20 mg Q3W + Pembrolizumab 200 mg Q3W n=2 Participants Participants received separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 70 mg Q3W + Pembrolizumab 200 mg Q3W n=7 Participants Participants received separate IV infusions of boserolimab 70 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 200 mg Q3W + Pembrolizumab 200 mg Q3W n=14 Participants Participants received separate IV infusions of boserolimab 200 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2a Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W (TNBC) n=30 Participants Participants with triple-negative breast cancer (TNBC) received separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2b Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W (Endometrial) n=15 Participants Participants with endometrial cancer received separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2c Boserolimab 30 mg Q6W + Pembrolizumab 400 mg Q6W (Endometrial) n=11 Participants Participants with endometrial cancer received separate IV infusions of boserolimab 30 mg and pembrolizumab 400 mg. Boserolimab was administered once Q6W on Day 1 of each cycle for a total of up to approximately 4 cycles (up to approximately 6 months). Pembrolizumab was administered once Q6W on Day 1 of each cycle for a total of up to approximately 18 cycles (up to approximately 27 months). Each cycle was 6 weeks long.	Arm 2 Boserolimab 2 mg Q3W + Pembrolizumab 200 mg Q3W n=2 Participants Participants received separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 7 mg Q3W + Pembrolizumab 200 mg Q3W n=3 Participants Participants received separate IV infusions of boserolimab 7 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 2 mg Q3W To Boserolimab 2 mg + Pembrolizumab 200 mg Q3W n=10 Participants Qualified participants who received boserolimab 2 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 7 mg Q3W To Boserolimab 2 mg + Pembrolizumab 200 mg Q3W n=40 Participants Qualified participants who received boserolimab 7 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 20 mg Q3W To Boserolimab 7 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 20 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 7 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 20 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 20 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 70 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 70 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 70 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 70 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 200 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 200 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1a Boserolimab 30mg Q3W (Endometrial) To Boserolimab 30mg + Pembrolizumab 200mg Q3W Qualified participants who received boserolimab 30 mg via IV infusion in Arm 1a but experienced disease progression switched over to receive separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.
Area Under the Concentration-Time Curve From Time 0 to Last Quantifiable Concentration (AUC0-last) of Boserolimab	0.761 day*μg/mL Geometric Coefficient of Variation 179	7.61 day*μg/mL Geometric Coefficient of Variation NA Method of dispersion could not be estimated due to n=1.	44.4 day*μg/mL Geometric Coefficient of Variation 28.6	150 day*μg/mL Geometric Coefficient of Variation 14.2	469 day*μg/mL Geometric Coefficient of Variation 42.9	918 day*μg/mL Geometric Coefficient of Variation 21.4	44.4 day*μg/mL Geometric Coefficient of Variation 51.7	26.1 day*μg/mL Geometric Coefficient of Variation 38.5	84.5 day*μg/mL Geometric Coefficient of Variation 192	646 day*μg/mL Geometric Coefficient of Variation 16.3	41.5 day*μg/mL Geometric Coefficient of Variation 109	44.9 day*μg/mL Geometric Coefficient of Variation 68.6	47.5 day*μg/mL Geometric Coefficient of Variation 58.5	0.816 day*μg/mL Geometric Coefficient of Variation 20.8	3.9 day*μg/mL Geometric Coefficient of Variation 117	41.6 day*μg/mL Geometric Coefficient of Variation 44.5	62.9 day*μg/mL Geometric Coefficient of Variation 57.8	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Predose Day 1 Cycle 1 and at designated timepoints up to Day 1 Cycle 2

Population: All participants who complied with the protocol sufficiently to ensure that the data was likely to exhibit the effects of treatment, according to the underlying scientific model, and who had available AUC0-3w data from ≥1 study treatment. As pre-specified in the protocol, PK outcomes were not analyzed separately for the Switch-over Arms.

AUC0-3w was defined as the area under the concentration versus time curve for boserolimab from 0 to 3 weeks in serum. Samples were taken predose and at specified times postdose to determine the AUC0-3w of boserolimab. PK collection time frames include: Arms 1, 2 (Cycle = 3 weeks): Predose, at start \& end of infusion on Day 1 Cycle 1, Days 2, 3, 5, 8, 15 of Cycle 1, and predose on Day 1 of Cycle 2; Arms 1a, 2a, 2b, 3 (Cycle = 3 weeks): Predose, at start \& end of infusion on Day 1 Cycle 1, Days 2, 3, 8, 15 of Cycle 1, and predose on Day 1 of Cycle 2; Arms 2c and 4 (Cycle = 6 weeks): Predose, at start \& end of infusion on Day 1 Cycle 1, Days 2, 3, 8, 15, 22 of Cycle 1.

Outcome measures

Outcome measures
Measure	Arm 1 Boserolimab 2 mg Q3W n=3 Participants Participants received boserolimab 2 mg via intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long	Arm 1 Boserolimab 7 mg Q3W n=1 Participants Participants received boserolimab 7 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 20 mg Q3W n=3 Participants Participants received boserolimab 20 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 70 mg Q3W n=3 Participants Participants received boserolimab 70 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 200 mg Q3W n=8 Participants Participants received boserolimab 200 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 700 mg Q3W n=2 Participants Participants received boserolimab 700 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1a Boserolimab 30 mg Q3W (Endometrial) n=14 Participants Participants with endometrial cancer received boserolimab 30 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 20 mg Q3W + Pembrolizumab 200 mg Q3W n=2 Participants Participants received separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 70 mg Q3W + Pembrolizumab 200 mg Q3W n=7 Participants Participants received separate IV infusions of boserolimab 70 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 200 mg Q3W + Pembrolizumab 200 mg Q3W n=14 Participants Participants received separate IV infusions of boserolimab 200 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2a Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W (TNBC) n=30 Participants Participants with triple-negative breast cancer (TNBC) received separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2b Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W (Endometrial) n=15 Participants Participants with endometrial cancer received separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2c Boserolimab 30 mg Q6W + Pembrolizumab 400 mg Q6W (Endometrial) n=11 Participants Participants with endometrial cancer received separate IV infusions of boserolimab 30 mg and pembrolizumab 400 mg. Boserolimab was administered once Q6W on Day 1 of each cycle for a total of up to approximately 4 cycles (up to approximately 6 months). Pembrolizumab was administered once Q6W on Day 1 of each cycle for a total of up to approximately 18 cycles (up to approximately 27 months). Each cycle was 6 weeks long.	Arm 2 Boserolimab 2 mg Q3W + Pembrolizumab 200 mg Q3W n=2 Participants Participants received separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 7 mg Q3W + Pembrolizumab 200 mg Q3W n=3 Participants Participants received separate IV infusions of boserolimab 7 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 2 mg Q3W To Boserolimab 2 mg + Pembrolizumab 200 mg Q3W n=10 Participants Qualified participants who received boserolimab 2 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 7 mg Q3W To Boserolimab 2 mg + Pembrolizumab 200 mg Q3W n=40 Participants Qualified participants who received boserolimab 7 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 20 mg Q3W To Boserolimab 7 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 20 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 7 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 20 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 20 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 70 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 70 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 70 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 70 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 200 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 200 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1a Boserolimab 30mg Q3W (Endometrial) To Boserolimab 30mg + Pembrolizumab 200mg Q3W Qualified participants who received boserolimab 30 mg via IV infusion in Arm 1a but experienced disease progression switched over to receive separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.
Area Under the Concentration-Time Curve From Time 0 to 3 Weeks (AUC0-3w) of Boserolimab	1.79 day*μg/mL Geometric Coefficient of Variation 111	7.77 day*μg/mL Geometric Coefficient of Variation NA Method of dispersion could not be estimated due to n = 1	44.4 day*μg/mL Geometric Coefficient of Variation 28.6	155 day*μg/mL Geometric Coefficient of Variation 7.85	531 day*μg/mL Geometric Coefficient of Variation 28.1	1060 day*μg/mL Geometric Coefficient of Variation 0.434	44.3 day*μg/mL Geometric Coefficient of Variation 54	28.1 day*μg/mL Geometric Coefficient of Variation 50.8	142 day*μg/mL Geometric Coefficient of Variation 63.3	661 day*μg/mL Geometric Coefficient of Variation 16.4	49.9 day*μg/mL Geometric Coefficient of Variation 41.3	50.5 day*μg/mL Geometric Coefficient of Variation 34.2	48.1 day*μg/mL Geometric Coefficient of Variation 42.5	1.2 day*μg/mL Geometric Coefficient of Variation 22	6.69 day*μg/mL Geometric Coefficient of Variation 47.5	42.2 day*μg/mL Geometric Coefficient of Variation 41.5	60.4 day*μg/mL Geometric Coefficient of Variation 39.5	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Arms 2c and 4 (Cycle = 6 weeks): Predose, at start & end of infusion on Day 1 Cycle 1, Days 2, 3, 8, 15, 22 of Cycle 1, and predose on Day 1 Cycle 2

Population: All participants in Arms 2c and 4 who complied with the protocol sufficiently to ensure that the data was likely to exhibit the effects of treatment, according to the underlying scientific model, and who had available AUC0-6w data from ≥1 study treatment. As pre-specified in the protocol, PK outcomes were not analyzed separately for the Switch-over Arms.

AUC0-6w was defined as the area under the concentration versus time curve for boserolimab from 0 to 6 weeks in serum. Samples were taken predose and at specified times postdose to determine the AUC0-6w of boserolimab. As pre-specified in the protocol, different arms had different sampling schedules and cycle lengths and therefore AUC0-6w was not analyzed for all Arms; AUC0-6w was only analyzed for Arms 2c and 4 which had 6-week cycles.

Outcome measures

Outcome measures
Measure	Arm 1 Boserolimab 2 mg Q3W n=11 Participants Participants received boserolimab 2 mg via intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long	Arm 1 Boserolimab 7 mg Q3W n=40 Participants Participants received boserolimab 7 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 20 mg Q3W Participants received boserolimab 20 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 70 mg Q3W Participants received boserolimab 70 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 200 mg Q3W Participants received boserolimab 200 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 700 mg Q3W Participants received boserolimab 700 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1a Boserolimab 30 mg Q3W (Endometrial) Participants with endometrial cancer received boserolimab 30 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 20 mg Q3W + Pembrolizumab 200 mg Q3W Participants received separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 70 mg Q3W + Pembrolizumab 200 mg Q3W Participants received separate IV infusions of boserolimab 70 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 200 mg Q3W + Pembrolizumab 200 mg Q3W Participants received separate IV infusions of boserolimab 200 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2a Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W (TNBC) Participants with triple-negative breast cancer (TNBC) received separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2b Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W (Endometrial) Participants with endometrial cancer received separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2c Boserolimab 30 mg Q6W + Pembrolizumab 400 mg Q6W (Endometrial) Participants with endometrial cancer received separate IV infusions of boserolimab 30 mg and pembrolizumab 400 mg. Boserolimab was administered once Q6W on Day 1 of each cycle for a total of up to approximately 4 cycles (up to approximately 6 months). Pembrolizumab was administered once Q6W on Day 1 of each cycle for a total of up to approximately 18 cycles (up to approximately 27 months). Each cycle was 6 weeks long.	Arm 2 Boserolimab 2 mg Q3W + Pembrolizumab 200 mg Q3W Participants received separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 7 mg Q3W + Pembrolizumab 200 mg Q3W Participants received separate IV infusions of boserolimab 7 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 2 mg Q3W To Boserolimab 2 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 2 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 7 mg Q3W To Boserolimab 2 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 7 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 20 mg Q3W To Boserolimab 7 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 20 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 7 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 20 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 20 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 70 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 70 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 70 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 70 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 200 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 200 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1a Boserolimab 30mg Q3W (Endometrial) To Boserolimab 30mg + Pembrolizumab 200mg Q3W Qualified participants who received boserolimab 30 mg via IV infusion in Arm 1a but experienced disease progression switched over to receive separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.
Area Under the Concentration-Time Curve From Time 0 to 6 Weeks (AUC0-6w) of Boserolimab	55 day*μg/mL Geometric Coefficient of Variation 49.2	68.3 day*μg/mL Geometric Coefficient of Variation 45.4	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Predose Day 1 Cycle 1 and at designated timepoints up to Day 1 Cycle 2

Population: All participants who complied with the protocol sufficiently to ensure that the data was likely to exhibit the effects of treatment, according to the underlying scientific model, and who had available Cmin data from ≥1 study treatment. As pre-specified in the protocol, PK outcomes were not analyzed separately for the Switch-over Arms.

Cmin of boserolimab was defined as the minimum concentration of boserolimab observed in serum. Samples were taken predose and at specified times postdose to determine the Cmin of boserolimab. PK collection time frames include: Arms 1, 2 (Cycle = 3 weeks): Predose, at start \& end of infusion on Day 1 Cycle 1, Days 2, 3, 5, 8, 15 of Cycle 1, and predose on Day 1 of Cycle 2; Arms 1a, 2a, 2b, 3 (Cycle = 3 weeks): Predose, at start \& end of infusion on Day 1 Cycle 1, Days 2, 3, 8, 15 of Cycle 1, and predose on Day 1 of Cycle 2; Arms 2c and 4 (Cycle = 6 weeks): Predose, at start \& end of infusion on Day 1 Cycle 1, Days 2, 3, 8, 15, 22 of Cycle 1, and predose on Day 1 of Cycle 2.

Outcome measures

Outcome measures
Measure	Arm 1 Boserolimab 2 mg Q3W n=3 Participants Participants received boserolimab 2 mg via intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long	Arm 1 Boserolimab 7 mg Q3W n=2 Participants Participants received boserolimab 7 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 20 mg Q3W n=3 Participants Participants received boserolimab 20 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 70 mg Q3W n=2 Participants Participants received boserolimab 70 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 200 mg Q3W n=5 Participants Participants received boserolimab 200 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 700 mg Q3W n=1 Participants Participants received boserolimab 700 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1a Boserolimab 30 mg Q3W (Endometrial) n=13 Participants Participants with endometrial cancer received boserolimab 30 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 20 mg Q3W + Pembrolizumab 200 mg Q3W n=3 Participants Participants received separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 70 mg Q3W + Pembrolizumab 200 mg Q3W n=5 Participants Participants received separate IV infusions of boserolimab 70 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 200 mg Q3W + Pembrolizumab 200 mg Q3W n=13 Participants Participants received separate IV infusions of boserolimab 200 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2a Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W (TNBC) n=26 Participants Participants with triple-negative breast cancer (TNBC) received separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2b Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W (Endometrial) n=15 Participants Participants with endometrial cancer received separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2c Boserolimab 30 mg Q6W + Pembrolizumab 400 mg Q6W (Endometrial) n=10 Participants Participants with endometrial cancer received separate IV infusions of boserolimab 30 mg and pembrolizumab 400 mg. Boserolimab was administered once Q6W on Day 1 of each cycle for a total of up to approximately 4 cycles (up to approximately 6 months). Pembrolizumab was administered once Q6W on Day 1 of each cycle for a total of up to approximately 18 cycles (up to approximately 27 months). Each cycle was 6 weeks long.	Arm 2 Boserolimab 2 mg Q3W + Pembrolizumab 200 mg Q3W n=2 Participants Participants received separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 7 mg Q3W + Pembrolizumab 200 mg Q3W n=2 Participants Participants received separate IV infusions of boserolimab 7 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 2 mg Q3W To Boserolimab 2 mg + Pembrolizumab 200 mg Q3W n=9 Participants Qualified participants who received boserolimab 2 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 7 mg Q3W To Boserolimab 2 mg + Pembrolizumab 200 mg Q3W n=36 Participants Qualified participants who received boserolimab 7 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 20 mg Q3W To Boserolimab 7 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 20 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 7 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 20 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 20 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 70 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 70 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 70 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 70 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 200 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 200 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1a Boserolimab 30mg Q3W (Endometrial) To Boserolimab 30mg + Pembrolizumab 200mg Q3W Qualified participants who received boserolimab 30 mg via IV infusion in Arm 1a but experienced disease progression switched over to receive separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.
Minimum Concentration (Cmin) of Boserolimab	NA μg/mL Standard Deviation NA For all 3 participants, plasma concentrations of boserolimab were below the limits of quantitation.	0.0689 μg/mL Standard Deviation 0.0975	0.421 μg/mL Standard Deviation 0.103	3.55 μg/mL Standard Deviation 0.573	15.5 μg/mL Standard Deviation 8.08	24.3 μg/mL Standard Deviation NA Method of dispersion could not be estimated due to n = 1	0.617 μg/mL Standard Deviation 0.498	0.0629 μg/mL Standard Deviation 0.0575	3.55 μg/mL Standard Deviation 3.37	16.2 μg/mL Standard Deviation 5.14	0.721 μg/mL Standard Deviation 0.505	0.610 μg/mL Standard Deviation 0.499	0.126 μg/mL Standard Deviation 0.258	NA μg/mL Standard Deviation NA For all 2 participants, plasma concentrations of boserolimab were below the limits of quantitation.	0.0283 μg/mL Standard Deviation 0.0400	0.471 μg/mL Standard Deviation 0.473	0.158 μg/mL Standard Deviation 0.340	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Predose Day 1 Cycle 1 and at designated timepoints up to Day 1 Cycle 2

Population: All participants who complied with the protocol sufficiently to ensure that the data was likely to exhibit the effects of treatment, according to the underlying scientific model, and who had available Cmax data from ≥1 study treatment. As pre-specified in the protocol, PK outcomes were not analyzed separately for the Switch-over Arms.

Cmax of boserolimab was defined as the maximum concentration of boserolimab observed in serum. Samples were taken predose and at specified times postdose to determine the Cmax of boserolimab. PK collection time frames include: Arms 1, 2 (Cycle = 3 weeks): Predose, at start \& end of infusion on Day 1 Cycle 1, Days 2, 3, 5, 8, 15 of Cycle 1, and predose on Day 1 of Cycle 2; Arms 1a, 2a, 2b, 3 (Cycle = 3 weeks): Predose, at start \& end of infusion on Day 1 Cycle 1, Days 2, 3, 8, 15 of Cycle 1, and predose on Day 1 of Cycle 2; Arms 2c and 4 (Cycle = 6 weeks): Predose, at start \& end of infusion on Day 1 Cycle 1, Days 2, 3, 8, 15, 22 of Cycle 1, and predose on Day 1 of Cycle 2.

Outcome measures

Outcome measures
Measure	Arm 1 Boserolimab 2 mg Q3W n=3 Participants Participants received boserolimab 2 mg via intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long	Arm 1 Boserolimab 7 mg Q3W n=1 Participants Participants received boserolimab 7 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 20 mg Q3W n=3 Participants Participants received boserolimab 20 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 70 mg Q3W n=3 Participants Participants received boserolimab 70 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 200 mg Q3W n=8 Participants Participants received boserolimab 200 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 700 mg Q3W n=2 Participants Participants received boserolimab 700 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1a Boserolimab 30 mg Q3W (Endometrial) n=14 Participants Participants with endometrial cancer received boserolimab 30 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 20 mg Q3W + Pembrolizumab 200 mg Q3W n=2 Participants Participants received separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 70 mg Q3W + Pembrolizumab 200 mg Q3W n=7 Participants Participants received separate IV infusions of boserolimab 70 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 200 mg Q3W + Pembrolizumab 200 mg Q3W n=14 Participants Participants received separate IV infusions of boserolimab 200 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2a Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W (TNBC) n=30 Participants Participants with triple-negative breast cancer (TNBC) received separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2b Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W (Endometrial) n=15 Participants Participants with endometrial cancer received separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2c Boserolimab 30 mg Q6W + Pembrolizumab 400 mg Q6W (Endometrial) n=11 Participants Participants with endometrial cancer received separate IV infusions of boserolimab 30 mg and pembrolizumab 400 mg. Boserolimab was administered once Q6W on Day 1 of each cycle for a total of up to approximately 4 cycles (up to approximately 6 months). Pembrolizumab was administered once Q6W on Day 1 of each cycle for a total of up to approximately 18 cycles (up to approximately 27 months). Each cycle was 6 weeks long.	Arm 2 Boserolimab 2 mg Q3W + Pembrolizumab 200 mg Q3W n=2 Participants Participants received separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 7 mg Q3W + Pembrolizumab 200 mg Q3W n=3 Participants Participants received separate IV infusions of boserolimab 7 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 2 mg Q3W To Boserolimab 2 mg + Pembrolizumab 200 mg Q3W n=10 Participants Qualified participants who received boserolimab 2 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 7 mg Q3W To Boserolimab 2 mg + Pembrolizumab 200 mg Q3W n=40 Participants Qualified participants who received boserolimab 7 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 20 mg Q3W To Boserolimab 7 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 20 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 7 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 20 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 20 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 70 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 70 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 70 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 70 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 200 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 200 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1a Boserolimab 30mg Q3W (Endometrial) To Boserolimab 30mg + Pembrolizumab 200mg Q3W Qualified participants who received boserolimab 30 mg via IV infusion in Arm 1a but experienced disease progression switched over to receive separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.
Maximum Concentration (Cmax) of Boserolimab	1.15 μg/mL Geometric Coefficient of Variation 175	3.32 μg/mL Geometric Coefficient of Variation NA Method of dispersion could not be estimated due to n = 1	8.16 μg/mL Geometric Coefficient of Variation 28.6	21.6 μg/mL Geometric Coefficient of Variation 22	67.8 μg/mL Geometric Coefficient of Variation 23.1	105 μg/mL Geometric Coefficient of Variation 8.71	7.24 μg/mL Geometric Coefficient of Variation 46.7	4.9 μg/mL Geometric Coefficient of Variation 39	26.9 μg/mL Geometric Coefficient of Variation 37	83.2 μg/mL Geometric Coefficient of Variation 16.6	7.89 μg/mL Geometric Coefficient of Variation 70.2	8.68 μg/mL Geometric Coefficient of Variation 24.6	8.27 μg/mL Geometric Coefficient of Variation 37.4	0.656 μg/mL Geometric Coefficient of Variation 5.08	1.75 μg/mL Geometric Coefficient of Variation 5.75	7.44 μg/mL Geometric Coefficient of Variation 37.3	9.39 μg/mL Geometric Coefficient of Variation 33.2	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Up to approximately 78 months

Population: All participants in Arm 1a, 2a, 2b, 2c, 4, and Switch-over Arm 1a with a baseline scan who demonstrated measurable disease by investigator assessment, and who were administered at least 1 dose of study treatment.

ORR was defined as the percentage of participants who had a Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) as assessed using RECIST 1.1. As pre-specified in the protocol, ORR was analyzed for participants treated with boserolimab when used as monotherapy in Arm 1a, in combination with pembrolizumab in Switch-over Arm 1a and Arms 2a, 2b, and 2c, or in combination with pembrolizumab + nab-paclitaxel in Arm 4. Per protocol, ORR was not analyzed in Arms 1, 2, or 3. The percentage of participants who experienced a CR or PR, as assessed by the investigator, is reported.

Outcome measures

Outcome measures
Measure	Arm 1 Boserolimab 2 mg Q3W n=14 Participants Participants received boserolimab 2 mg via intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long	Arm 1 Boserolimab 7 mg Q3W n=30 Participants Participants received boserolimab 7 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 20 mg Q3W n=15 Participants Participants received boserolimab 20 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 70 mg Q3W n=13 Participants Participants received boserolimab 70 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 200 mg Q3W n=41 Participants Participants received boserolimab 200 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 700 mg Q3W n=9 Participants Participants received boserolimab 700 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1a Boserolimab 30 mg Q3W (Endometrial) Participants with endometrial cancer received boserolimab 30 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 20 mg Q3W + Pembrolizumab 200 mg Q3W Participants received separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 70 mg Q3W + Pembrolizumab 200 mg Q3W Participants received separate IV infusions of boserolimab 70 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 200 mg Q3W + Pembrolizumab 200 mg Q3W Participants received separate IV infusions of boserolimab 200 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2a Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W (TNBC) Participants with triple-negative breast cancer (TNBC) received separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2b Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W (Endometrial) Participants with endometrial cancer received separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2c Boserolimab 30 mg Q6W + Pembrolizumab 400 mg Q6W (Endometrial) Participants with endometrial cancer received separate IV infusions of boserolimab 30 mg and pembrolizumab 400 mg. Boserolimab was administered once Q6W on Day 1 of each cycle for a total of up to approximately 4 cycles (up to approximately 6 months). Pembrolizumab was administered once Q6W on Day 1 of each cycle for a total of up to approximately 18 cycles (up to approximately 27 months). Each cycle was 6 weeks long.	Arm 2 Boserolimab 2 mg Q3W + Pembrolizumab 200 mg Q3W Participants received separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 7 mg Q3W + Pembrolizumab 200 mg Q3W Participants received separate IV infusions of boserolimab 7 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 2 mg Q3W To Boserolimab 2 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 2 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 7 mg Q3W To Boserolimab 2 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 7 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 20 mg Q3W To Boserolimab 7 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 20 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 7 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 20 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 20 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 70 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 70 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 70 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 70 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 200 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 200 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1a Boserolimab 30mg Q3W (Endometrial) To Boserolimab 30mg + Pembrolizumab 200mg Q3W Qualified participants who received boserolimab 30 mg via IV infusion in Arm 1a but experienced disease progression switched over to receive separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.
Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)	7.1 Percentage of Participants Interval 0.2 to 33.9	20.0 Percentage of Participants Interval 7.7 to 38.6	13.3 Percentage of Participants Interval 1.7 to 40.5	0.0 Percentage of Participants Interval 0.0 to 24.7	53.7 Percentage of Participants Interval 37.4 to 69.3	11.1 Percentage of Participants Interval 0.3 to 48.2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Up to 21 days in Cycle 1

Population: All participants in Arm 3 who received ≥1 dose of study treatment and who were observed for DLTs for up to 21 days following the first dose of study treatment in Cycle 1.

Outcome measures

Outcome measures
Measure	Arm 1 Boserolimab 2 mg Q3W n=10 Participants Participants received boserolimab 2 mg via intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long	Arm 1 Boserolimab 7 mg Q3W Participants received boserolimab 7 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 20 mg Q3W Participants received boserolimab 20 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 70 mg Q3W Participants received boserolimab 70 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 200 mg Q3W Participants received boserolimab 200 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 700 mg Q3W Participants received boserolimab 700 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1a Boserolimab 30 mg Q3W (Endometrial) Participants with endometrial cancer received boserolimab 30 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 20 mg Q3W + Pembrolizumab 200 mg Q3W Participants received separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 70 mg Q3W + Pembrolizumab 200 mg Q3W Participants received separate IV infusions of boserolimab 70 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 200 mg Q3W + Pembrolizumab 200 mg Q3W Participants received separate IV infusions of boserolimab 200 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2a Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W (TNBC) Participants with triple-negative breast cancer (TNBC) received separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2b Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W (Endometrial) Participants with endometrial cancer received separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2c Boserolimab 30 mg Q6W + Pembrolizumab 400 mg Q6W (Endometrial) Participants with endometrial cancer received separate IV infusions of boserolimab 30 mg and pembrolizumab 400 mg. Boserolimab was administered once Q6W on Day 1 of each cycle for a total of up to approximately 4 cycles (up to approximately 6 months). Pembrolizumab was administered once Q6W on Day 1 of each cycle for a total of up to approximately 18 cycles (up to approximately 27 months). Each cycle was 6 weeks long.	Arm 2 Boserolimab 2 mg Q3W + Pembrolizumab 200 mg Q3W Participants received separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 7 mg Q3W + Pembrolizumab 200 mg Q3W Participants received separate IV infusions of boserolimab 7 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 2 mg Q3W To Boserolimab 2 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 2 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 7 mg Q3W To Boserolimab 2 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 7 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 20 mg Q3W To Boserolimab 7 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 20 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 7 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 20 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 20 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 70 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 70 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 70 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 70 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 200 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 200 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1a Boserolimab 30mg Q3W (Endometrial) To Boserolimab 30mg + Pembrolizumab 200mg Q3W Qualified participants who received boserolimab 30 mg via IV infusion in Arm 1a but experienced disease progression switched over to receive separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.
Arm 3: Number of Participants Who Experienced a DLT	0 Participants	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Up to 28 days in Cycle 1

Population: All participants in Arm 4 who received ≥1 dose of study treatment and who were observed for DLTs for up to 28 days following the first dose of study treatment in Cycle 1.

Outcome measures

Outcome measures
Measure	Arm 1 Boserolimab 2 mg Q3W n=41 Participants Participants received boserolimab 2 mg via intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long	Arm 1 Boserolimab 7 mg Q3W Participants received boserolimab 7 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 20 mg Q3W Participants received boserolimab 20 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 70 mg Q3W Participants received boserolimab 70 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 200 mg Q3W Participants received boserolimab 200 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 700 mg Q3W Participants received boserolimab 700 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1a Boserolimab 30 mg Q3W (Endometrial) Participants with endometrial cancer received boserolimab 30 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 20 mg Q3W + Pembrolizumab 200 mg Q3W Participants received separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 70 mg Q3W + Pembrolizumab 200 mg Q3W Participants received separate IV infusions of boserolimab 70 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 200 mg Q3W + Pembrolizumab 200 mg Q3W Participants received separate IV infusions of boserolimab 200 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2a Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W (TNBC) Participants with triple-negative breast cancer (TNBC) received separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2b Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W (Endometrial) Participants with endometrial cancer received separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2c Boserolimab 30 mg Q6W + Pembrolizumab 400 mg Q6W (Endometrial) Participants with endometrial cancer received separate IV infusions of boserolimab 30 mg and pembrolizumab 400 mg. Boserolimab was administered once Q6W on Day 1 of each cycle for a total of up to approximately 4 cycles (up to approximately 6 months). Pembrolizumab was administered once Q6W on Day 1 of each cycle for a total of up to approximately 18 cycles (up to approximately 27 months). Each cycle was 6 weeks long.	Arm 2 Boserolimab 2 mg Q3W + Pembrolizumab 200 mg Q3W Participants received separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 7 mg Q3W + Pembrolizumab 200 mg Q3W Participants received separate IV infusions of boserolimab 7 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 2 mg Q3W To Boserolimab 2 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 2 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 7 mg Q3W To Boserolimab 2 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 7 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 20 mg Q3W To Boserolimab 7 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 20 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 7 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 20 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 20 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 70 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 70 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 70 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 70 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 200 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 200 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1a Boserolimab 30mg Q3W (Endometrial) To Boserolimab 30mg + Pembrolizumab 200mg Q3W Qualified participants who received boserolimab 30 mg via IV infusion in Arm 1a but experienced disease progression switched over to receive separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.
Arm 4: Number of Participants Who Experienced a DLT	1 Participants	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Up to 57 months

Population: All participants in Arms 3 or 4 who received ≥1 dose of study treatment.

Outcome measures

Outcome measures
Measure	Arm 1 Boserolimab 2 mg Q3W n=10 Participants Participants received boserolimab 2 mg via intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long	Arm 1 Boserolimab 7 mg Q3W n=41 Participants Participants received boserolimab 7 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 20 mg Q3W Participants received boserolimab 20 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 70 mg Q3W Participants received boserolimab 70 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 200 mg Q3W Participants received boserolimab 200 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 700 mg Q3W Participants received boserolimab 700 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1a Boserolimab 30 mg Q3W (Endometrial) Participants with endometrial cancer received boserolimab 30 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 20 mg Q3W + Pembrolizumab 200 mg Q3W Participants received separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 70 mg Q3W + Pembrolizumab 200 mg Q3W Participants received separate IV infusions of boserolimab 70 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 200 mg Q3W + Pembrolizumab 200 mg Q3W Participants received separate IV infusions of boserolimab 200 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2a Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W (TNBC) Participants with triple-negative breast cancer (TNBC) received separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2b Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W (Endometrial) Participants with endometrial cancer received separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2c Boserolimab 30 mg Q6W + Pembrolizumab 400 mg Q6W (Endometrial) Participants with endometrial cancer received separate IV infusions of boserolimab 30 mg and pembrolizumab 400 mg. Boserolimab was administered once Q6W on Day 1 of each cycle for a total of up to approximately 4 cycles (up to approximately 6 months). Pembrolizumab was administered once Q6W on Day 1 of each cycle for a total of up to approximately 18 cycles (up to approximately 27 months). Each cycle was 6 weeks long.	Arm 2 Boserolimab 2 mg Q3W + Pembrolizumab 200 mg Q3W Participants received separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 7 mg Q3W + Pembrolizumab 200 mg Q3W Participants received separate IV infusions of boserolimab 7 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 2 mg Q3W To Boserolimab 2 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 2 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 7 mg Q3W To Boserolimab 2 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 7 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 20 mg Q3W To Boserolimab 7 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 20 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 7 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 20 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 20 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 70 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 70 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 70 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 70 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 200 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 200 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1a Boserolimab 30mg Q3W (Endometrial) To Boserolimab 30mg + Pembrolizumab 200mg Q3W Qualified participants who received boserolimab 30 mg via IV infusion in Arm 1a but experienced disease progression switched over to receive separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.
Arm 3 and 4: Number of Participants With One or More AEs	10 Participants	41 Participants	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Up to 27 months

Population: All participants in Arms 3 or 4 who received ≥1 dose of study treatment.

Outcome measures

Outcome measures
Measure	Arm 1 Boserolimab 2 mg Q3W n=10 Participants Participants received boserolimab 2 mg via intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long	Arm 1 Boserolimab 7 mg Q3W n=41 Participants Participants received boserolimab 7 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 20 mg Q3W Participants received boserolimab 20 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 70 mg Q3W Participants received boserolimab 70 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 200 mg Q3W Participants received boserolimab 200 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 700 mg Q3W Participants received boserolimab 700 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1a Boserolimab 30 mg Q3W (Endometrial) Participants with endometrial cancer received boserolimab 30 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 20 mg Q3W + Pembrolizumab 200 mg Q3W Participants received separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 70 mg Q3W + Pembrolizumab 200 mg Q3W Participants received separate IV infusions of boserolimab 70 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 200 mg Q3W + Pembrolizumab 200 mg Q3W Participants received separate IV infusions of boserolimab 200 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2a Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W (TNBC) Participants with triple-negative breast cancer (TNBC) received separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2b Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W (Endometrial) Participants with endometrial cancer received separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2c Boserolimab 30 mg Q6W + Pembrolizumab 400 mg Q6W (Endometrial) Participants with endometrial cancer received separate IV infusions of boserolimab 30 mg and pembrolizumab 400 mg. Boserolimab was administered once Q6W on Day 1 of each cycle for a total of up to approximately 4 cycles (up to approximately 6 months). Pembrolizumab was administered once Q6W on Day 1 of each cycle for a total of up to approximately 18 cycles (up to approximately 27 months). Each cycle was 6 weeks long.	Arm 2 Boserolimab 2 mg Q3W + Pembrolizumab 200 mg Q3W Participants received separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 7 mg Q3W + Pembrolizumab 200 mg Q3W Participants received separate IV infusions of boserolimab 7 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 2 mg Q3W To Boserolimab 2 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 2 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 7 mg Q3W To Boserolimab 2 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 7 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 20 mg Q3W To Boserolimab 7 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 20 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 7 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 20 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 20 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 70 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 70 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 70 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 70 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 200 mg + Pembrolizumab 200 mg Q3W Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 200 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1a Boserolimab 30mg Q3W (Endometrial) To Boserolimab 30mg + Pembrolizumab 200mg Q3W Qualified participants who received boserolimab 30 mg via IV infusion in Arm 1a but experienced disease progression switched over to receive separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.
Arm 3 and 4: Number of Participants Who Discontinued Study Treatment Due to an AE	2 Participants	6 Participants	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

Adverse Events

Arm 1 Boserolimab 700 mg Q3W

Serious events: 1 serious events

Other events: 2 other events

Deaths: 2 deaths

Arm 1 Boserolimab 2 mg Q3W

Serious events: 1 serious events

Other events: 3 other events

Deaths: 2 deaths

Arm 1 Boserolimab 7 mg Q3W

Serious events: 0 serious events

Other events: 3 other events

Deaths: 2 deaths

Arm 1 Boserolimab 20 mg Q3W

Serious events: 0 serious events

Other events: 6 other events

Deaths: 1 deaths

Arm 1 Boserolimab 70 mg Q3W

Serious events: 0 serious events

Other events: 3 other events

Deaths: 1 deaths

Arm 1 Boserolimab 200 mg Q3W

Serious events: 1 serious events

Other events: 8 other events

Deaths: 3 deaths

Arm 1a Boserolimab 30 mg Q3W (Endometrial)

Serious events: 2 serious events

Other events: 14 other events

Deaths: 5 deaths

Arm 2 Boserolimab 2 mg Q3W + Pembrolizumab 200 mg Q3W

Serious events: 1 serious events

Other events: 3 other events

Deaths: 3 deaths

Arm 2 Boserolimab 7 mg Q3W + Pembrolizumab 200 mg Q3W

Serious events: 0 serious events

Other events: 3 other events

Deaths: 3 deaths

Arm 2 Boserolimab 20 mg Q3W + Pembrolizumab 200 mg Q3W

Serious events: 1 serious events

Other events: 3 other events

Deaths: 4 deaths

Arm 2 Boserolimab 70 mg Q3W + Pembrolizumab 200 mg Q3W

Serious events: 1 serious events

Other events: 7 other events

Deaths: 7 deaths

Arm 2 Boserolimab 200 mg Q3W + Pembrolizumab 200 mg Q3W

Serious events: 3 serious events

Other events: 14 other events

Deaths: 12 deaths

Arm 2a Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W (TNBC)

Serious events: 11 serious events

Other events: 30 other events

Deaths: 29 deaths

Arm 2b Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W (Endometrial)

Serious events: 2 serious events

Other events: 15 other events

Deaths: 14 deaths

Arm 2c Boserolimab 30 mg Q6W + Pembrolizumab 400 mg Q6W (Endometrial)

Serious events: 0 serious events

Other events: 13 other events

Deaths: 10 deaths

Arm 3 Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W + Pemetrexed + Carboplatin (NSCLC)

Serious events: 9 serious events

Other events: 10 other events

Deaths: 8 deaths

Arm 4 Boserolimab 30 mg Q6W + Pembrolizumab 400 mg Q6W + Nab-paclitaxel (TNBC)

Serious events: 13 serious events

Other events: 40 other events

Deaths: 18 deaths

Switch-over Arm 1 Boserolimab 2 mg Q3W To Boserolimab 2 mg + Pembrolizumab 200 mg Q3W

Serious events: 0 serious events

Other events: 1 other events

Deaths: 0 deaths

Switch-over Arm 1 Boserolimab 7 mg Q3W To Boserolimab 2 mg + Pembrolizumab 200 mg Q3W

Serious events: 0 serious events

Other events: 1 other events

Deaths: 1 deaths

Switch-over Arm 1 Boserolimab 20 mg Q3W To Boserolimab 7 mg + Pembrolizumab 200 mg Q3W

Serious events: 1 serious events

Other events: 2 other events

Deaths: 2 deaths

Switch-over Arm 1 Boserolimab 20 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W

Serious events: 1 serious events

Other events: 3 other events

Deaths: 2 deaths

Switch-over Arm 1 Boserolimab 70 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W

Serious events: 0 serious events

Other events: 2 other events

Deaths: 1 deaths

Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W

Serious events: 2 serious events

Other events: 2 other events

Deaths: 2 deaths

Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 70 mg + Pembrolizumab 200 mg Q3W

Serious events: 0 serious events

Other events: 2 other events

Deaths: 0 deaths

Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 200 mg + Pembrolizumab 200 mg Q3W

Serious events: 0 serious events

Other events: 1 other events

Deaths: 1 deaths

Switch-over Arm 1a Boserolimab 30mg Q3W (Endometrial) To Boserolimab 30mg + Pembrolizumab 200mg Q3W

Serious events: 3 serious events

Other events: 8 other events

Deaths: 6 deaths

Serious adverse events

Serious adverse events
Measure	Arm 1 Boserolimab 700 mg Q3W n=2 participants at risk Participants received boserolimab 700 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long	Arm 1 Boserolimab 2 mg Q3W n=3 participants at risk Participants received boserolimab 2 mg via intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 7 mg Q3W n=3 participants at risk Participants received boserolimab 7 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long	Arm 1 Boserolimab 20 mg Q3W n=6 participants at risk Participants received boserolimab 20 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long	Arm 1 Boserolimab 70 mg Q3W n=3 participants at risk Participants received boserolimab 70 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 200 mg Q3W n=8 participants at risk Participants received boserolimab 200 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1a Boserolimab 30 mg Q3W (Endometrial) n=14 participants at risk Participants with endometrial cancer received boserolimab 30 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 2 mg Q3W + Pembrolizumab 200 mg Q3W n=3 participants at risk Participants received separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 7 mg Q3W + Pembrolizumab 200 mg Q3W n=3 participants at risk Participants received separate IV infusions of boserolimab 7 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 20 mg Q3W + Pembrolizumab 200 mg Q3W n=3 participants at risk Participants received separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long	Arm 2 Boserolimab 70 mg Q3W + Pembrolizumab 200 mg Q3W n=7 participants at risk Participants received separate IV infusions of boserolimab 70 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 200 mg Q3W + Pembrolizumab 200 mg Q3W n=14 participants at risk Participants received separate IV infusions of boserolimab 200 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2a Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W (TNBC) n=30 participants at risk Participants with triple-negative breast cancer (TNBC) received separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2b Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W (Endometrial) n=15 participants at risk Participants with endometrial cancer received separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2c Boserolimab 30 mg Q6W + Pembrolizumab 400 mg Q6W (Endometrial) n=13 participants at risk Participants with endometrial cancer received separate IV infusions of boserolimab 30 mg and pembrolizumab 400 mg. Boserolimab was administered once Q6W on Day 1 of each cycle for a total of up to approximately 4 cycles (up to approximately 6 months). Pembrolizumab was administered once Q6W on Day 1 of each cycle for a total of up to approximately 18 cycles (up to approximately 27 months). Each cycle was 6 weeks long.	Arm 3 Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W + Pemetrexed + Carboplatin (NSCLC) n=10 participants at risk Participants with non-small cell lung cancer (NSCLC) received separate IV infusions of boserolimab 30 mg, pembrolizumab 200 mg, pemetrexed 500 mg/m\^2, and carboplatin area under the curve (AUC) 5 mg/mL/min. Boserolimab was administered once Q3W on Day 1 of each cycle for a total of up to approximately 8 cycles (up to approximately 6 months). Pembrolizumab and pemetrexed were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Carboplatin was administered once Q3W on Day 1 of each cycle for a total of up to approximately 4 cycles (up to approximately 3 months). Each cycle was 3 weeks long.	Arm 4 Boserolimab 30 mg Q6W + Pembrolizumab 400 mg Q6W + Nab-paclitaxel (TNBC) n=41 participants at risk Participants with TNBC received separate IV infusions of boserolimab 30 mg, pembrolizumab 400 mg, and nab-paclitaxel 100 mg/m\^2. Boserolimab and pembrolizumab were administered once Q6W on Day 1 of each cycle for a total of up to approximately 18 cycles (up to approximately 27 months). Nab-paclitaxel was administered on a 3-weeks on/1-week off schedule every 28 days (Days 1, 8, 15, 29, and 36 of odd-numbered cycles and Days 1, 15, 22, and 29 of even-numbered cycles). Each cycle was 6 weeks long.	Switch-over Arm 1 Boserolimab 2 mg Q3W To Boserolimab 2 mg + Pembrolizumab 200 mg Q3W n=1 participants at risk Qualified participants who received boserolimab 2 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 7 mg Q3W To Boserolimab 2 mg + Pembrolizumab 200 mg Q3W n=1 participants at risk Qualified participants who received boserolimab 7 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 20 mg Q3W To Boserolimab 7 mg + Pembrolizumab 200 mg Q3W n=2 participants at risk Qualified participants who received boserolimab 20 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 7 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 20 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W n=3 participants at risk Qualified participants who received boserolimab 20 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 70 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W n=2 participants at risk Qualified participants who received boserolimab 70 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W n=2 participants at risk Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 70 mg + Pembrolizumab 200 mg Q3W n=2 participants at risk Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 70 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 200 mg + Pembrolizumab 200 mg Q3W n=1 participants at risk Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 200 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1a Boserolimab 30mg Q3W (Endometrial) To Boserolimab 30mg + Pembrolizumab 200mg Q3W n=9 participants at risk Qualified participants who received boserolimab 30 mg via IV infusion in Arm 1a but experienced disease progression switched over to receive separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.
Cardiac disorders Pericarditis constrictive	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Endocrine disorders Adrenal insufficiency	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Endocrine disorders Inappropriate antidiuretic hormone secretion	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Endocrine disorders Thyroiditis	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Gastrointestinal disorders Abdominal pain	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	50.0% 1/2 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Gastrointestinal disorders Constipation	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Gastrointestinal disorders Diarrhoea	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Gastrointestinal disorders Haemorrhoidal haemorrhage	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Gastrointestinal disorders Immune-mediated gastritis	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
General disorders Chest pain	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
General disorders Complication associated with device	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
General disorders Fatigue	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
General disorders Malaise	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
General disorders Multiple organ dysfunction syndrome	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
General disorders Oedema peripheral	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.5% 1/8 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
General disorders Pyrexia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
General disorders Sudden death	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Hepatobiliary disorders Cholecystitis	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Hepatobiliary disorders Hepatic haemorrhage	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Immune system disorders Cytokine release syndrome	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Infections and infestations COVID-19	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Infections and infestations COVID-19 pneumonia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Infections and infestations Cellulitis	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	20.0% 2/10 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Infections and infestations Cystitis	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Infections and infestations Pneumonia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	20.0% 2/10 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Infections and infestations Pneumonia bacterial	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Infections and infestations Pulmonary sepsis	50.0% 1/2 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Infections and infestations Respiratory tract infection	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Infections and infestations Wound infection	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Injury, poisoning and procedural complications Infusion related reaction	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	4.9% 2/41 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Injury, poisoning and procedural complications Lumbar vertebral fracture	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Injury, poisoning and procedural complications Multiple fractures	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Injury, poisoning and procedural complications Post procedural haematuria	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Investigations Neutrophil count decreased	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Investigations Platelet count decreased	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	20.0% 2/10 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Investigations White blood cell count decreased	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Metabolism and nutrition disorders Hyperglycaemia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.5% 1/8 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Musculoskeletal and connective tissue disorders Bone pain	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Musculoskeletal and connective tissue disorders Intervertebral disc protrusion	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour pain	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Nervous system disorders Ataxia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Nervous system disorders Encephalitis autoimmune	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Nervous system disorders Epilepsy	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Nervous system disorders Hemiparesis	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Nervous system disorders Myasthenia gravis	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	50.0% 1/2 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Nervous system disorders Peripheral sensory neuropathy	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Renal and urinary disorders Acute kidney injury	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	50.0% 1/2 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Renal and urinary disorders Haematuria	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Renal and urinary disorders Tubulointerstitial nephritis	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Renal and urinary disorders Urinary tract obstruction	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 3/30 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	20.0% 2/10 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Vascular disorders Hypotension	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 1/7 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Vascular disorders Lymphoedema	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Vascular disorders Thrombosis	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.

Other adverse events

Other adverse events
Measure	Arm 1 Boserolimab 700 mg Q3W n=2 participants at risk Participants received boserolimab 700 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long	Arm 1 Boserolimab 2 mg Q3W n=3 participants at risk Participants received boserolimab 2 mg via intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 7 mg Q3W n=3 participants at risk Participants received boserolimab 7 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long	Arm 1 Boserolimab 20 mg Q3W n=6 participants at risk Participants received boserolimab 20 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long	Arm 1 Boserolimab 70 mg Q3W n=3 participants at risk Participants received boserolimab 70 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1 Boserolimab 200 mg Q3W n=8 participants at risk Participants received boserolimab 200 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 1a Boserolimab 30 mg Q3W (Endometrial) n=14 participants at risk Participants with endometrial cancer received boserolimab 30 mg via IV infusion once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 2 mg Q3W + Pembrolizumab 200 mg Q3W n=3 participants at risk Participants received separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 7 mg Q3W + Pembrolizumab 200 mg Q3W n=3 participants at risk Participants received separate IV infusions of boserolimab 7 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 20 mg Q3W + Pembrolizumab 200 mg Q3W n=3 participants at risk Participants received separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long	Arm 2 Boserolimab 70 mg Q3W + Pembrolizumab 200 mg Q3W n=7 participants at risk Participants received separate IV infusions of boserolimab 70 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2 Boserolimab 200 mg Q3W + Pembrolizumab 200 mg Q3W n=14 participants at risk Participants received separate IV infusions of boserolimab 200 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2a Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W (TNBC) n=30 participants at risk Participants with triple-negative breast cancer (TNBC) received separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2b Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W (Endometrial) n=15 participants at risk Participants with endometrial cancer received separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Each cycle was 3 weeks long.	Arm 2c Boserolimab 30 mg Q6W + Pembrolizumab 400 mg Q6W (Endometrial) n=13 participants at risk Participants with endometrial cancer received separate IV infusions of boserolimab 30 mg and pembrolizumab 400 mg. Boserolimab was administered once Q6W on Day 1 of each cycle for a total of up to approximately 4 cycles (up to approximately 6 months). Pembrolizumab was administered once Q6W on Day 1 of each cycle for a total of up to approximately 18 cycles (up to approximately 27 months). Each cycle was 6 weeks long.	Arm 3 Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W + Pemetrexed + Carboplatin (NSCLC) n=10 participants at risk Participants with non-small cell lung cancer (NSCLC) received separate IV infusions of boserolimab 30 mg, pembrolizumab 200 mg, pemetrexed 500 mg/m\^2, and carboplatin area under the curve (AUC) 5 mg/mL/min. Boserolimab was administered once Q3W on Day 1 of each cycle for a total of up to approximately 8 cycles (up to approximately 6 months). Pembrolizumab and pemetrexed were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years). Carboplatin was administered once Q3W on Day 1 of each cycle for a total of up to approximately 4 cycles (up to approximately 3 months). Each cycle was 3 weeks long.	Arm 4 Boserolimab 30 mg Q6W + Pembrolizumab 400 mg Q6W + Nab-paclitaxel (TNBC) n=41 participants at risk Participants with TNBC received separate IV infusions of boserolimab 30 mg, pembrolizumab 400 mg, and nab-paclitaxel 100 mg/m\^2. Boserolimab and pembrolizumab were administered once Q6W on Day 1 of each cycle for a total of up to approximately 18 cycles (up to approximately 27 months). Nab-paclitaxel was administered on a 3-weeks on/1-week off schedule every 28 days (Days 1, 8, 15, 29, and 36 of odd-numbered cycles and Days 1, 15, 22, and 29 of even-numbered cycles). Each cycle was 6 weeks long.	Switch-over Arm 1 Boserolimab 2 mg Q3W To Boserolimab 2 mg + Pembrolizumab 200 mg Q3W n=1 participants at risk Qualified participants who received boserolimab 2 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 7 mg Q3W To Boserolimab 2 mg + Pembrolizumab 200 mg Q3W n=1 participants at risk Qualified participants who received boserolimab 7 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 2 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 20 mg Q3W To Boserolimab 7 mg + Pembrolizumab 200 mg Q3W n=2 participants at risk Qualified participants who received boserolimab 20 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 7 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 20 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W n=3 participants at risk Qualified participants who received boserolimab 20 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 70 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W n=2 participants at risk Qualified participants who received boserolimab 70 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 20 mg + Pembrolizumab 200 mg Q3W n=2 participants at risk Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 20 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 70 mg + Pembrolizumab 200 mg Q3W n=2 participants at risk Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 70 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1 Boserolimab 200 mg Q3W To Boserolimab 200 mg + Pembrolizumab 200 mg Q3W n=1 participants at risk Qualified participants who received boserolimab 200 mg via IV infusion in Arm 1 but experienced disease progression switched over to receive separate IV infusions of boserolimab 200 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.	Switch-over Arm 1a Boserolimab 30mg Q3W (Endometrial) To Boserolimab 30mg + Pembrolizumab 200mg Q3W n=9 participants at risk Qualified participants who received boserolimab 30 mg via IV infusion in Arm 1a but experienced disease progression switched over to receive separate IV infusions of boserolimab 30 mg and pembrolizumab 200 mg. Boserolimab and pembrolizumab were administered once Q3W on Day 1 of each cycle for a total of up to approximately 35 cycles (up to approximately 2 years) after switch-over. Each cycle was 3 weeks long.
Blood and lymphatic system disorders Anaemia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 2/14 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 2/14 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	13.3% 2/15 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.7% 1/13 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	50.0% 5/10 • Number of events 5 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	43.9% 18/41 • Number of events 54 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	100.0% 1/1 • Number of events 4 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	50.0% 1/2 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Blood and lymphatic system disorders Iron deficiency anaemia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.7% 1/13 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Blood and lymphatic system disorders Leukopenia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	22.0% 9/41 • Number of events 60 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Blood and lymphatic system disorders Lymphadenopathy mediastinal	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 1/7 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Blood and lymphatic system disorders Lymphopenia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Blood and lymphatic system disorders Neutropenia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	30.0% 3/10 • Number of events 7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	24.4% 10/41 • Number of events 65 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Blood and lymphatic system disorders Thrombocytopenia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	40.0% 4/10 • Number of events 6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Blood and lymphatic system disorders Thrombocytosis	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Cardiac disorders Palpitations	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	100.0% 1/1 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Cardiac disorders Sinus tachycardia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	16.7% 5/30 • Number of events 5 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Ear and labyrinth disorders Ear pain	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 1/7 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 2/30 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Ear and labyrinth disorders Tinnitus	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	4.9% 2/41 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Ear and labyrinth disorders Vertigo	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Ear and labyrinth disorders Vertigo positional	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Endocrine disorders Autoimmune thyroiditis	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.7% 1/13 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Endocrine disorders Cushingoid	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Endocrine disorders Hyperthyroidism	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	13.3% 4/30 • Number of events 4 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.7% 1/13 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.3% 3/41 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	100.0% 1/1 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Endocrine disorders Hypothyroidism	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	16.7% 1/6 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.7% 1/13 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	17.1% 7/41 • Number of events 7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	50.0% 1/2 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Eye disorders Dry eye	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	20.0% 2/10 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	9.8% 4/41 • Number of events 4 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Eye disorders Eye discharge	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Eye disorders Eyelid oedema	50.0% 1/2 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Eye disorders Keratitis	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Eye disorders Lacrimation increased	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	4.9% 2/41 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Eye disorders Scleral disorder	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Eye disorders Ulcerative keratitis	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	16.7% 1/6 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Eye disorders Vision blurred	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 1/7 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	50.0% 1/2 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Eye disorders Visual impairment	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Eye disorders Vitreous floaters	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Gastrointestinal disorders Abdominal discomfort	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.7% 1/13 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Gastrointestinal disorders Abdominal distension	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 2/14 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	15.4% 2/13 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	50.0% 1/2 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Gastrointestinal disorders Abdominal pain	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	66.7% 2/3 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	50.0% 3/6 • Number of events 4 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.5% 1/8 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 2/14 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	13.3% 4/30 • Number of events 5 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	15.4% 2/13 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	20.0% 2/10 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.2% 5/41 • Number of events 10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	100.0% 1/1 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	66.7% 2/3 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Gastrointestinal disorders Abdominal pain lower	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Gastrointestinal disorders Abdominal pain upper	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	16.7% 1/6 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.2% 5/41 • Number of events 5 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Gastrointestinal disorders Anal incontinence	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Gastrointestinal disorders Ascites	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 1/7 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.7% 1/13 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Gastrointestinal disorders Constipation	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	66.7% 2/3 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.5% 1/8 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 1/7 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	21.4% 3/14 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	16.7% 5/30 • Number of events 6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	13.3% 2/15 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	30.0% 3/10 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	31.7% 13/41 • Number of events 19 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	22.2% 2/9 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Gastrointestinal disorders Diarrhoea	50.0% 1/2 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	16.7% 1/6 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	37.5% 3/8 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 1/7 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 3/30 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	40.0% 6/15 • Number of events 10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.7% 1/13 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	50.0% 5/10 • Number of events 9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	43.9% 18/41 • Number of events 45 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	100.0% 1/1 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Gastrointestinal disorders Dry mouth	50.0% 1/2 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 1/7 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 2/30 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	13.3% 2/15 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.7% 1/13 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.3% 3/41 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Gastrointestinal disorders Dyspepsia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	19.5% 8/41 • Number of events 8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Gastrointestinal disorders Dysphagia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	16.7% 1/6 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Gastrointestinal disorders Faeces soft	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 1/7 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	100.0% 1/1 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Gastrointestinal disorders Flatulence	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 1/7 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	4.9% 2/41 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Gastrointestinal disorders Frequent bowel movements	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Gastrointestinal disorders Gastrointestinal obstruction	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Gastrointestinal disorders Gastrointestinal pain	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.5% 1/8 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Gastrointestinal disorders Gastrooesophageal reflux disease	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.5% 1/8 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Gastrointestinal disorders Glossodynia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Gastrointestinal disorders Haemorrhoidal haemorrhage	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Gastrointestinal disorders Haemorrhoids	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	100.0% 1/1 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Gastrointestinal disorders Hiatus hernia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	100.0% 1/1 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Gastrointestinal disorders Mouth ulceration	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Gastrointestinal disorders Nausea	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	66.7% 4/6 • Number of events 4 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	25.0% 2/8 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 2/14 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	66.7% 2/3 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	66.7% 2/3 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	28.6% 2/7 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 2/14 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	40.0% 12/30 • Number of events 16 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	26.7% 4/15 • Number of events 5 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	38.5% 5/13 • Number of events 7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	50.0% 5/10 • Number of events 8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	53.7% 22/41 • Number of events 33 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	100.0% 1/1 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	50.0% 1/2 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Gastrointestinal disorders Odynophagia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Gastrointestinal disorders Oral dysaesthesia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Gastrointestinal disorders Oral pain	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.5% 1/8 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 1/7 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Gastrointestinal disorders Proctalgia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Gastrointestinal disorders Rectal haemorrhage	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Gastrointestinal disorders Rectal tenesmus	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 1/7 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Gastrointestinal disorders Stomatitis	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	29.3% 12/41 • Number of events 26 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Gastrointestinal disorders Tongue disorder	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Gastrointestinal disorders Vomiting	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	66.7% 4/6 • Number of events 4 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.5% 1/8 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 2/14 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 1/7 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 2/14 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	30.0% 9/30 • Number of events 13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	13.3% 2/15 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	15.4% 2/13 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	26.8% 11/41 • Number of events 15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	50.0% 1/2 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
General disorders Asthenia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	20.0% 3/15 • Number of events 4 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	15.4% 2/13 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.2% 5/41 • Number of events 9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
General disorders Axillary pain	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	50.0% 1/2 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
General disorders Chest pain	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	16.7% 1/6 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	4.9% 2/41 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
General disorders Chills	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	16.7% 1/6 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.5% 1/8 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	28.6% 4/14 • Number of events 6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	40.0% 12/30 • Number of events 13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	15.4% 2/13 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	4.9% 2/41 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	50.0% 1/2 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
General disorders Face oedema	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	20.0% 2/10 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.3% 3/41 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
General disorders Fatigue	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	66.7% 2/3 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	66.7% 2/3 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	50.0% 3/6 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.5% 1/8 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	21.4% 3/14 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	66.7% 2/3 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	85.7% 6/7 • Number of events 7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	64.3% 9/14 • Number of events 10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	60.0% 18/30 • Number of events 20 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	26.7% 4/15 • Number of events 6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	23.1% 3/13 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	60.0% 6/10 • Number of events 7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	61.0% 25/41 • Number of events 41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	100.0% 1/1 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	66.7% 2/3 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
General disorders Feeling of body temperature change	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
General disorders General physical health deterioration	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.7% 1/13 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
General disorders Influenza like illness	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	16.7% 1/6 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	25.0% 2/8 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	66.7% 2/3 • Number of events 7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 1/7 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	26.7% 8/30 • Number of events 8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	50.0% 1/2 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
General disorders Infusion site extravasation	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	100.0% 1/1 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
General disorders Localised oedema	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 2/30 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
General disorders Malaise	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 2/30 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
General disorders Mucosal inflammation	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	20.0% 2/10 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	9.8% 4/41 • Number of events 4 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
General disorders Non-cardiac chest pain	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 2/30 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
General disorders Oedema	50.0% 1/2 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.6% 6/41 • Number of events 6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
General disorders Oedema peripheral	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 2/14 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	26.7% 4/15 • Number of events 4 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.7% 1/13 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	20.0% 2/10 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.6% 6/41 • Number of events 10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	50.0% 1/2 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
General disorders Pain	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	16.7% 1/6 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
General disorders Peripheral swelling	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	50.0% 1/2 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
General disorders Pyrexia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.5% 1/8 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 2/14 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	100.0% 3/3 • Number of events 5 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	66.7% 2/3 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	21.4% 3/14 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	56.7% 17/30 • Number of events 25 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	22.0% 9/41 • Number of events 9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	66.7% 2/3 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	50.0% 1/2 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
General disorders Swelling face	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
General disorders Xerosis	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.6% 6/41 • Number of events 6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Hepatobiliary disorders Hyperbilirubinaemia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Hepatobiliary disorders Hypertransaminasaemia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Infections and infestations Abscess	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 1/7 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Infections and infestations Asymptomatic bacteriuria	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Infections and infestations Body tinea	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.5% 1/8 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Infections and infestations COVID-19	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	24.4% 10/41 • Number of events 11 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	22.2% 2/9 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Infections and infestations Cellulitis	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	4.9% 2/41 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Infections and infestations Conjunctivitis	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.7% 1/13 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.3% 3/41 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Infections and infestations Cystitis	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	100.0% 1/1 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Infections and infestations Device related infection	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Infections and infestations Eye infection	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Infections and infestations Genital infection	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Infections and infestations Herpes ophthalmic	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Infections and infestations Herpes zoster	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	100.0% 3/3 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 1/7 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	4.9% 2/41 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	50.0% 1/2 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Infections and infestations Lip infection	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Infections and infestations Lower respiratory tract infection	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Infections and infestations Mucosal infection	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.7% 1/13 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Infections and infestations Nasopharyngitis	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 2/14 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	24.4% 10/41 • Number of events 15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	100.0% 1/1 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Infections and infestations Oral candidiasis	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Infections and infestations Oral infection	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Infections and infestations Otitis externa	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Infections and infestations Pharyngitis	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Infections and infestations Pneumonia	50.0% 1/2 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	40.0% 4/10 • Number of events 5 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	9.8% 4/41 • Number of events 4 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Infections and infestations Respiratory tract infection	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	4.9% 2/41 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Infections and infestations Respiratory tract infection viral	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.3% 3/41 • Number of events 4 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Infections and infestations Rhinitis	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	4.9% 2/41 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Infections and infestations Sinusitis	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Infections and infestations Skin infection	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	4.9% 2/41 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Infections and infestations Upper respiratory tract infection	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.5% 1/8 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	15.4% 2/13 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	30.0% 3/10 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	9.8% 4/41 • Number of events 5 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	100.0% 1/1 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Infections and infestations Urinary tract infection	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	16.7% 1/6 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	15.4% 2/13 • Number of events 4 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	9.8% 4/41 • Number of events 4 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	22.2% 2/9 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Infections and infestations Vascular device infection	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Infections and infestations Vulvovaginal candidiasis	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Injury, poisoning and procedural complications Arthropod sting	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Injury, poisoning and procedural complications Bone contusion	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Injury, poisoning and procedural complications Contusion	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Injury, poisoning and procedural complications Foot fracture	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Injury, poisoning and procedural complications Infusion related reaction	100.0% 2/2 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	66.7% 2/3 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	16.7% 1/6 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.5% 1/8 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	42.9% 6/14 • Number of events 6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	28.6% 2/7 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	28.6% 4/14 • Number of events 5 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 10/30 • Number of events 11 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	26.7% 4/15 • Number of events 5 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	38.5% 5/13 • Number of events 6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.2% 5/41 • Number of events 6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	50.0% 1/2 • Number of events 7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 3/9 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Injury, poisoning and procedural complications Ligament sprain	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Injury, poisoning and procedural complications Post procedural haemorrhage	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Injury, poisoning and procedural complications Procedural pain	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 1/7 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Injury, poisoning and procedural complications Radiation necrosis	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Injury, poisoning and procedural complications Thermal burn	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Investigations Alanine aminotransferase increased	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.5% 1/8 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 2/14 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	20.0% 6/30 • Number of events 6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	15.4% 2/13 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	20.0% 2/10 • Number of events 4 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	34.1% 14/41 • Number of events 27 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Investigations Amylase increased	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	26.8% 11/41 • Number of events 23 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Investigations Aspartate aminotransferase increased	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.5% 1/8 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 2/14 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	16.7% 5/30 • Number of events 5 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	23.1% 3/13 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	20.0% 2/10 • Number of events 7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	36.6% 15/41 • Number of events 26 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	50.0% 1/2 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Investigations Blood albumin decreased	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	20.0% 2/10 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	9.8% 4/41 • Number of events 5 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Investigations Blood alkaline phosphatase increased	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.7% 1/13 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Investigations Blood bilirubin increased	50.0% 1/2 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.5% 1/8 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	13.3% 2/15 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	4.9% 2/41 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Investigations Blood calcium decreased	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	9.8% 4/41 • Number of events 8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Investigations Blood cholesterol increased	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.2% 5/41 • Number of events 7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Investigations Blood creatinine increased	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.5% 1/8 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 1/7 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.7% 1/13 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	20.0% 2/10 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.2% 5/41 • Number of events 8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Investigations Blood glucose increased	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	9.8% 4/41 • Number of events 8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Investigations Blood iron decreased	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Investigations Blood lactate dehydrogenase increased	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 4 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Investigations Blood potassium decreased	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.2% 5/41 • Number of events 13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Investigations Blood sodium decreased	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.3% 3/41 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Investigations Blood sodium increased	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 5 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Investigations Blood thyroid stimulating hormone increased	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	4.9% 2/41 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Investigations Blood uric acid increased	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	20.0% 2/10 • Number of events 4 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Investigations Cardiac murmur	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Investigations Gamma-glutamyltransferase increased	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.7% 1/13 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	20.0% 2/10 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Investigations Haemoglobin decreased	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 2/14 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	30.0% 3/10 • Number of events 6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Investigations Lipase increased	50.0% 1/2 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	36.6% 15/41 • Number of events 38 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Investigations Lymphocyte count decreased	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	30.0% 3/10 • Number of events 4 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	4.9% 2/41 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Investigations Neutrophil count decreased	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	40.0% 4/10 • Number of events 6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	31.7% 13/41 • Number of events 35 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Investigations Platelet count decreased	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	40.0% 4/10 • Number of events 6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.3% 3/41 • Number of events 4 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Investigations SARS-CoV-2 test positive	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Investigations Serum ferritin decreased	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Investigations Transaminases increased	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.7% 1/13 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Investigations Weight decreased	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.5% 1/8 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	13.3% 2/15 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.6% 6/41 • Number of events 6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Investigations Weight increased	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	4.9% 2/41 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Investigations White blood cell count decreased	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	40.0% 4/10 • Number of events 4 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.3% 3/41 • Number of events 4 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Metabolism and nutrition disorders Decreased appetite	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.5% 1/8 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 2/14 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 1/7 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 2/14 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 3/30 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	13.3% 2/15 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.7% 1/13 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	30.0% 3/10 • Number of events 5 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	24.4% 10/41 • Number of events 13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	22.2% 2/9 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Metabolism and nutrition disorders Dehydration	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Metabolism and nutrition disorders Hyperglycaemia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.6% 6/41 • Number of events 13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Metabolism and nutrition disorders Hyperkalaemia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.7% 1/13 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Metabolism and nutrition disorders Hypernatraemia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Metabolism and nutrition disorders Hyperphosphataemia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Metabolism and nutrition disorders Hyperuricaemia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.7% 1/13 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	4.9% 2/41 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Metabolism and nutrition disorders Hypoalbuminaemia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	9.8% 4/41 • Number of events 9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Metabolism and nutrition disorders Hypocalcaemia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Metabolism and nutrition disorders Hypokalaemia	50.0% 1/2 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.5% 1/8 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	15.4% 2/13 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	20.0% 2/10 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	4.9% 2/41 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Metabolism and nutrition disorders Hypomagnesaemia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.7% 1/13 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.7% 1/13 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Metabolism and nutrition disorders Hypophosphataemia	50.0% 1/2 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 4 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Metabolism and nutrition disorders Iron deficiency	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 2/14 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	16.7% 5/30 • Number of events 5 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	30.0% 3/10 • Number of events 10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	22.0% 9/41 • Number of events 16 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	100.0% 1/1 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Musculoskeletal and connective tissue disorders Arthritis	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.5% 1/8 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	100.0% 2/2 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	16.7% 5/30 • Number of events 5 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	13.3% 2/15 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	20.0% 2/10 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	22.0% 9/41 • Number of events 9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	66.7% 2/3 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Musculoskeletal and connective tissue disorders Bone pain	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	20.0% 2/10 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	4.9% 2/41 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Musculoskeletal and connective tissue disorders Coccydynia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Musculoskeletal and connective tissue disorders Flank pain	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	4.9% 2/41 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Musculoskeletal and connective tissue disorders Groin pain	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 2/14 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Musculoskeletal and connective tissue disorders Joint stiffness	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Musculoskeletal and connective tissue disorders Muscle spasms	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	16.7% 1/6 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Musculoskeletal and connective tissue disorders Muscular weakness	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.5% 1/8 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.5% 1/8 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 3/30 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	20.0% 2/10 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	19.5% 8/41 • Number of events 8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	50.0% 1/2 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Musculoskeletal and connective tissue disorders Musculoskeletal stiffness	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 2/6 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.5% 1/8 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	28.6% 2/7 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	13.3% 4/30 • Number of events 4 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	20.0% 3/15 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	41.5% 17/41 • Number of events 22 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	50.0% 1/2 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Musculoskeletal and connective tissue disorders Myalgia intercostal	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Musculoskeletal and connective tissue disorders Neck pain	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	16.7% 1/6 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 2/14 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	16.7% 5/30 • Number of events 5 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	9.8% 4/41 • Number of events 4 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 3/30 • Number of events 5 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	20.0% 3/15 • Number of events 4 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	9.8% 4/41 • Number of events 4 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Musculoskeletal and connective tissue disorders Pain in jaw	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Musculoskeletal and connective tissue disorders Polymyalgia rheumatica	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Musculoskeletal and connective tissue disorders Vertebral column mass	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Basal cell carcinoma	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Cancer pain	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.3% 3/41 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour associated fever	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour haemorrhage	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour pain	50.0% 1/2 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	28.6% 2/7 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	20.0% 3/15 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Nervous system disorders Bell's palsy	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Nervous system disorders Dizziness	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 1/7 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 2/14 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	20.0% 6/30 • Number of events 6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	13.3% 2/15 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	22.0% 9/41 • Number of events 9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	100.0% 1/1 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Nervous system disorders Dysgeusia	50.0% 1/2 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 2/30 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.6% 6/41 • Number of events 7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Nervous system disorders Headache	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.5% 1/8 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	66.7% 2/3 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	42.9% 3/7 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	16.7% 5/30 • Number of events 5 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.7% 1/13 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	20.0% 2/10 • Number of events 4 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	29.3% 12/41 • Number of events 15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	50.0% 1/2 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	50.0% 1/2 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Nervous system disorders Loss of consciousness	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Nervous system disorders Neuropathy peripheral	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.3% 3/41 • Number of events 5 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Nervous system disorders Paraesthesia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.7% 1/13 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Nervous system disorders Peripheral sensory neuropathy	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	39.0% 16/41 • Number of events 17 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Nervous system disorders Psychomotor hyperactivity	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Nervous system disorders Radiculopathy	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Nervous system disorders Somnolence	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 2/30 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Nervous system disorders Taste disorder	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Nervous system disorders VIth nerve paresis	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Psychiatric disorders Anxiety	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 2/14 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Psychiatric disorders Depression	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	4.9% 2/41 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Psychiatric disorders Insomnia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.5% 1/8 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	17.1% 7/41 • Number of events 8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	50.0% 1/2 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Renal and urinary disorders Acute kidney injury	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	13.3% 2/15 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Renal and urinary disorders Chronic kidney disease	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.5% 1/8 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Renal and urinary disorders Dysuria	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	50.0% 1/2 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Renal and urinary disorders Haematuria	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.7% 1/13 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Renal and urinary disorders Hydronephrosis	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Renal and urinary disorders Pollakiuria	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Renal and urinary disorders Urinary incontinence	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Renal and urinary disorders Urinary retention	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Renal and urinary disorders Urinary tract pain	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Renal and urinary disorders Urogenital fistula	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.7% 1/13 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Reproductive system and breast disorders Breast inflammation	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.5% 1/8 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Reproductive system and breast disorders Breast pain	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 2/30 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	4.9% 2/41 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Reproductive system and breast disorders Coital bleeding	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	100.0% 1/1 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Reproductive system and breast disorders Pelvic pain	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 1/7 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Reproductive system and breast disorders Vaginal discharge	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.7% 1/13 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Reproductive system and breast disorders Vaginal haemorrhage	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 2/14 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Reproductive system and breast disorders Vulvovaginal discomfort	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Respiratory, thoracic and mediastinal disorders Bronchiectasis	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	16.7% 1/6 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 1/7 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	21.4% 3/14 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	13.3% 4/30 • Number of events 5 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	13.3% 2/15 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	30.0% 3/10 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	31.7% 13/41 • Number of events 19 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	50.0% 1/2 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	22.2% 2/9 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Respiratory, thoracic and mediastinal disorders Dysphonia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	4.9% 2/41 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	28.6% 2/7 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	20.0% 6/30 • Number of events 6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	15.4% 2/13 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	30.0% 3/10 • Number of events 4 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.2% 5/41 • Number of events 5 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Respiratory, thoracic and mediastinal disorders Dyspnoea exertional	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Respiratory, thoracic and mediastinal disorders Eosinophilic pneumonia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Respiratory, thoracic and mediastinal disorders Epistaxis	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Respiratory, thoracic and mediastinal disorders Haemoptysis	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.5% 1/8 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 2/30 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Respiratory, thoracic and mediastinal disorders Nasal congestion	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Respiratory, thoracic and mediastinal disorders Oropharyngeal discomfort	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	16.7% 1/6 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 1/7 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	4.9% 2/41 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	50.0% 1/2 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.5% 1/8 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.3% 3/41 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Respiratory, thoracic and mediastinal disorders Pneumothorax	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 1/7 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Respiratory, thoracic and mediastinal disorders Productive cough	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.3% 3/41 • Number of events 8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	4.9% 2/41 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Respiratory, thoracic and mediastinal disorders Pulmonary haemorrhage	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Respiratory, thoracic and mediastinal disorders Respiratory disorder	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Respiratory, thoracic and mediastinal disorders Rhinitis allergic	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Respiratory, thoracic and mediastinal disorders Rhinorrhoea	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.2% 5/41 • Number of events 5 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Skin and subcutaneous tissue disorders Alopecia	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 3/30 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	48.8% 20/41 • Number of events 20 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Skin and subcutaneous tissue disorders Decubitus ulcer	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Skin and subcutaneous tissue disorders Dermatitis	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 2/14 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Skin and subcutaneous tissue disorders Dry skin	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	13.3% 4/30 • Number of events 4 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Skin and subcutaneous tissue disorders Eczema	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	16.7% 1/6 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Skin and subcutaneous tissue disorders Erythema	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.5% 1/8 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 1/7 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 2/30 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	50.0% 1/2 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Skin and subcutaneous tissue disorders Hyperhidrosis	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Skin and subcutaneous tissue disorders Macule	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Skin and subcutaneous tissue disorders Nail disorder	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	9.8% 4/41 • Number of events 4 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Skin and subcutaneous tissue disorders Palmar-plantar erythrodysaesthesia syndrome	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.2% 5/41 • Number of events 6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Skin and subcutaneous tissue disorders Papule	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 2/30 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Skin and subcutaneous tissue disorders Pruritus	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	16.7% 1/6 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	25.0% 2/8 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	21.4% 3/14 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	28.6% 2/7 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	50.0% 7/14 • Number of events 7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	36.7% 11/30 • Number of events 11 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	13.3% 2/15 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	15.4% 2/13 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	20.0% 2/10 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	53.7% 22/41 • Number of events 29 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	100.0% 1/1 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	100.0% 1/1 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	66.7% 2/3 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	50.0% 1/2 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	100.0% 1/1 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	22.2% 2/9 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Skin and subcutaneous tissue disorders Psoriasis	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	50.0% 1/2 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Skin and subcutaneous tissue disorders Rash	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 1/7 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 2/14 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 2/30 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	20.0% 2/10 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	41.5% 17/41 • Number of events 27 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	100.0% 1/1 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	50.0% 1/2 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Skin and subcutaneous tissue disorders Rash macular	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	9.8% 4/41 • Number of events 4 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Skin and subcutaneous tissue disorders Rash maculo-papular	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	25.0% 2/8 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	21.4% 3/14 • Number of events 4 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	16.7% 5/30 • Number of events 5 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	26.7% 4/15 • Number of events 5 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.7% 1/13 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	30.0% 3/10 • Number of events 3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	19.5% 8/41 • Number of events 12 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	100.0% 2/2 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	100.0% 1/1 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Skin and subcutaneous tissue disorders Rash papular	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	10.0% 1/10 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Skin and subcutaneous tissue disorders Scar pain	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Skin and subcutaneous tissue disorders Seborrhoeic dermatitis	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	16.7% 1/6 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Skin and subcutaneous tissue disorders Skin burning sensation	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Skin and subcutaneous tissue disorders Skin lesion	50.0% 1/2 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Skin and subcutaneous tissue disorders Skin reaction	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Skin and subcutaneous tissue disorders Urticaria	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	13.3% 2/15 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Vascular disorders Deep vein thrombosis	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Vascular disorders Embolism	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Vascular disorders Flushing	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.7% 1/13 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Vascular disorders Haematoma	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Vascular disorders Hot flush	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Vascular disorders Hypertension	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 2/14 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	33.3% 1/3 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	3.3% 1/30 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	15.4% 2/13 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	12.2% 5/41 • Number of events 10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Vascular disorders Hypotension	50.0% 1/2 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 2/30 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Vascular disorders Lymphoedema	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	14.3% 1/7 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	2.4% 1/41 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	11.1% 1/9 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Vascular disorders Peripheral coldness	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	6.7% 1/15 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.
Vascular disorders Vena cava embolism	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/6 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/8 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	7.1% 1/14 • Number of events 1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/7 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/14 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/30 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/15 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/13 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/10 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/41 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/3 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/2 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/1 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.	0.00% 0/9 • Up to approximately 78 months Serious \& other AEs: all participants who received ≥1 dose of study drug. All-Cause Mortality (ACM): all enrolled participants. Per protocol, progression of cancer under study was not considered an AE unless related to study drug; MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression" \& "Disease progression" not related to study treatment are excluded as AEs. ACM and AEs are reported according to the treatment received by the participant at the time of the event.

Additional Information

Senior Vice President, Global Clinical Development

Merck Sharp & Dohme LLC

Phone: 1-800-672-6372

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial prior to submission. Any information identified by the Sponsor as confidential must be deleted prior to submission. This confidentiality does not include efficacy and safety results. The Sponsor will comply with the requirements for publication of study results. In accordance with standard editorial and ethical practice, the Sponsor will generally support publication.
Publication restrictions are in place

Restriction type: OTHER